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 1 
INTRODUCTION 
 
The Genomic Era and Genomics in Medical Records 
 
In 2003, the conclusion of the human genome project officially brought a start to the 
“genomic era” 1. With the start of the genomic era came the beginning of widespread and 
multiplex searches for genetic variants that caused diseases. Simultaneously, the presence of a 
human reference sequence allowed for the development of new genotyping platforms and new 
analysis methods, including the development of genome-wide association studies (GWAS).  
GWAS tests the association of one phenotype with all genotypes available from GWAS 
chips. GWAS chips use tagging single nucleotide polymorphisms (SNPs) as a proxy for variants 
that were in linkage disequilibrium, so that not all variants had to be tested
2
. In 2005 the first 
successful GWASs were published
3–5
. Despite this initial success, and other success stories 
through the years, GWAS has failed to identify as much of the heritability of common diseases 
as expected
6
. The variants identified in GWAS as associated with a disease are not necessarily 
the causal variants, rather the associated SNP may be linked to the causal variant. Even in well 
powered studies, the process of identifying the causal gene and variant extends well after the 
performance of GWAS. 
Importantly, GWAS studies frequently used ascertained case-control populations, which 
required significant time and money to assemble. Groups of cases with shared controls were 
developed, but this was not feasible for all phenotypes that investigators had found to be 
heritable and expected a genetic effect. Performing studies in an electronic medical record 
(EMR), also called an electronic health record (EHR), can be very cost effective compared to 
assembling a case control population
7
. 
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The predecessors of electronic medical records appeared as early as the 1960s. Now, 
more than 50 years later, their uptake continues today. A study from 2009 estimated that only 
1.5% of hospitals had a comprehensive electronic health record system 
8
. The Health Information 
Technology for Economic and Clinical Health (HITECH) Act of 2009 directed the Office of the 
National Coordinator for Health Information Technology (ONC) to promote the adoption and 
meaningful use of electronic health records. More recent estimates indicate that 3 out of 4 
hospitals have a basic EHR system
9
. A variety of information is available from EHRs. Billing 
data, laboratory data, vitals, medication lists, test results, and provider notes are all typically part 
of EMR data 
10
.  Billing data most often consists of International Classification of Disease (ICD) 
and Current Procedural Terminology (CPT) codes. EHRs also contain demographic information 
including age, sex, and physician reported race. 
ICD codes are developed and maintained by the World Health Organization 
(http://www.who.int/classifications/icd/en/HistoryOfICD.pdf). They are a hierarchical way to 
classify diseases and symptoms. The original purpose was to obtain morbidity and mortality 
statistics from around the world. The ICD system has been adapted for use in billing by hospitals 
and insurance companies. ICD is currently in version 10.  CPT codes are a way to identify 
clinical services and procedures for a medical encounter. They are designed and maintained by 
the American Medical Association
11
.  
Importantly, the information contained in medical records is not designed for research 
purposes. The information in medical records is also subject to provider preferences and habits, 
both at the physician and institutional level.  Coding expectations and preferences may vary from 
one medical center to another. Despite this, phenotyping algorithms developed at one medical 
center have been adapted for use at others, though a skilled team is often necessary to 
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successfully deploy it
10
. Additionally, if incorrect information gets in to a medical record, it can 
be difficult to remove it. Medical records are not edited, rather they are amended, with a 
clarifying or correcting note added. This not may not be seen by providers, so incorrect 
information may be propagated through an individuals’ record.  Information in the medical 
record may also depend on the accuracy of information a patient may tell their provider. Patients 
may give an incomplete or incorrect medical history which can influence notes in a record. 
Despite this, there is evidence that studies performed in the EMR can robustly replicate studies 
performed in more traditionally assembled cohorts
12
, and that this phenotyping is of sufficient 
quality for genetic analyses
13
. 
Many of the replication attempts using EMRs focus on associations discovered through 
GWAS. An EHR based study of 21 SNPs implicated in 5 common diseases found that the 
direction of effect of all SNPs tested was in the direction expected. In each disease at least one 
previously reported SNP association was replicated
11
. This study also manually reviewed their 
cases and found that their algorithms had greater than a 95% PPV for each of the 5 phenotypes 
studied. Another study on Rheumatoid Arthritis used a multi-ethnic EHR derived cohort to 
replicate a genetic risk score for rheumatoid arthritis
14
. Some reports also indicate that the 
longitudinal nature of the data in the EMR can assist in differentiating between related 
phenotypes
12
.  
 
BioVU and the Synthetic Derivative  
 
  The Synthetic Derivative (SD) is a de-identified mirror of the EMR from Vanderbilt 
University Medical Center. Several steps are taken to ensure de-identification of records. 
Records numbers go through a one-way hash to be assigned a number for that cannot be traced 
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back to the patient. Additionally, all Health Insurance Portability and Accountability Act 
(HIPAA) identifiers are removed from records. This includes names of individuals (both patients 
and health care providers). All dates in the record are shifted by 1-365 days, consistent within a 
record but variable between records. De-identified records are then available for research 
purposes. Due to the de-identification procedures, the SD has received a non-human subjects 
designation
15
.  
The Vanderbilt DNA Databank, BioVU, uses blood samples leftover from clinical testing 
as a source of DNA
16
. Samples banked are blood remnants that would otherwise be discarded. 
Initially, the DNA databank operated using an “opt-out” model. A statement was included in the 
consent to treat form describing the databank, and patients could opt out by checking a box. This 
resource was linked to de-identified medical records in the SD. In January of 2015, the consent 
process shifted to an opt-in model. Patients now have the option to consent to their samples 
being added to the DNA Databank. The blood samples are linked to de-identified entries in the 
SD. Individuals who had undergone hypertransfusion or bone marrow transplant are flagged as 
having compromised samples. Blood samples are available to be pulled for genotyping, and 
some samples have pre-existing genotype data available.  
Genotyping has been performed on a subset of samples within BioVU. This genotyping is 
paid for by individual investigators for individual research projects, so specific phenotype groups 
are genotyped in specific platforms leading to potential phenotype differences in the populations 
with data available from any given genotyping platform. The existing genotype information is 
everything from Taqman on single SNPs to platforms targeting SNPs in specific pathways, to 
GWAS platforms. Investigators can apply to use existing data for new projects.  
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PheWAS: Theory and Methods 
 
The underlying goal of PheWAS is to test the association of one variant with a range of 
phenotypes. In addition to the discovery of new disease genotype associations, PheWAS allows 
for the discovery of pleiotropy, the ability of a single gene or genetic variant to influence 
multiple traits, and an increased understanding of how phenotypes are related to each other
17
. 
PheWAS can also help differentiate between pleiotropy and comorbidities, and in some cases 
can differentiate between disease subtypes
18
. Many existing associations between genotypes and 
phenotypes have been replicated with PheWAS. PheWAS have also identified novel SNP-
phenotype associations. Despite this, some argue that one of the major accomplishments of 
PheWAS is the establishment of workflows to analyze and visualize complex and multi-
dimensional phenotype-genotype relationships
19
.  
PheWAS using ICD-9 codes for case control classification have repeatedly replicated or 
validated genotype-phenotype associations. The first PheWAS paper replicated seven SNP 
disease associations with p-values of at least 0.05 and odds ratios in the same direction as 
previous studies
20
.  Another study focused on systematically comparing PheWAS results to 
associations previously found in GWAS, mapped existing significantly associated GWAS traits 
to PheWAS phenotypes, determined that they were able to replicate 28% of all tested 
associations with a p-value <0.05 and a consistent direction of effect
21
. Once the authors filtered 
this to only binary GWAS traits with an exact match in the PheWAS catalog that was adequately 
powered in their study, they were able to replicate 66% of SNP-phenotype associations tested.  
Existing PheWAS have successfully shown variants to be pleiotropic. The idea of a 
single genetic factor resulting in multiple phenotypic outcomes is not new; studies going back 
many years have evaluated pleiotropy
22
. GWAS provides information about the correlation 
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between genomic variants, but analyzing only one phenotype at a time does not provide any 
information about the interconnected nature of phenotypes and disease outcomes. While 
pleiotropy has not been systematically studies in human complex trait genetics, it has been 
observed in human Mendelian disease genetics
23
. Several studies have looked at the influence of 
single SNPs on multiple related phenotypes such as immune phenotypes
24
 or cancers
25,26
. A 
recent study evaluated 42 traits with GWAS data, and found 341 pleiotropic loci; some of which 
were associated with unexpected phenotypes given the gene function
27
. Pleiotropy can influence 
multiple diseases through distinct pathways or because one disease is in the pathway of another. 
Looking across the entirety of diseases in the medical record has the potential to enhance our 
understanding of biology by drawing connections between different phenotypes. What is unique 
about PheWAS is situating it in the breadth of phenotype data available in an individual’s EMR.  
As there are many types of information contained in the EMR, a PheWAS could test any 
type of information that could be obtained for a sufficient number of subjects. PheWAS have 
been published using aggregated International Classification of Disease version 9 (ICD-9) 
codes
20
, but natural language processing (NLP) obtained strings, and lab values, or CPT codes 
are all possible starting points for phenotype determination. The PheWAS discussed in this 
dissertation will all use the most basic ICD-9 code aggregation method as a starting point.  
A scheme of aggregating and further hierarchically clustering ICD-9 codes into PheWAS codes 
(Phecodes) was developed and published in the first PheWAS manuscript
20
. Over time, the 
aggregation has been update several times. Using instances of the ICD-9 codes and aggregation 
rules, an individual may be classified as a case, control, or exclusion for a specific PheWAS code 
(Figure 0-A). Individuals can be excluded for multiple reasons: they can have some, but fewer 
than the desired number of ICD-9 codes in their record; or they can appear to be a control, but be 
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a case for something highly related. These exclusions can be used to limit falsely classifying 
individuals as either a case or a control when there is uncertainty or messiness in the record. 
These case/control classifications are then used as the outcome in logistic regression. 
Alternatively, the number of ICD-9 codes in a record can be used as an outcome in linear 
regression.  
 
 
Figure 0-A. Decision flow for classifying an individual as a case, control, or exclusion for 
PheWAS. After classification, individuals are assembled into a PheWAS table where all cells in 
a row indicates whether that individual is a case, control, or exclusion for each PheWAS code, 
and all cells of a column indicate the classification of each individual for that code. 
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In our analyses individuals were required to have two different ICD-9 codes that mapped 
to a Phecode or one ICD-9 code on multiple days (therefore multiple times in their record) in 
order to be considered a case (Figure 0-A). Individuals who had a single instance of an ICD-9 
code and no other ICD-9 codes that mapped to that Phecode were excluded. Individuals who had 
no ICD-9 codes in a Phecode and no exclusions for that Phecode became a control.  
Phecodes can also be grouped into specific phenotype areas, such as “Neoplasms”. This 
gives an added layer of possible aggregation. This aggregation may increase the difficulty of 
what is already the most difficult part of PheWAS, the interpretation of results. It could also 
potentially allow a more specific view. If only one group of phenotypes are of interest, one could 
analyze only that group and ignore the ICD-9 and Phecode record that groups outside the area of 
interest. It is important to note that Phecodes in the same group are often correlated, in some 
cases highly correlated. But Phecodes in separate code groups may be highly correlated or even 
indicative of the same underlying condition depending on the relationship of the ICD-9 
contributing to each.  
About this Dissertation 
 
 While the underlying theme of the work in this dissertation is PheWAS, it is important to 
note that each project described in this dissertation has a slightly different motivation that both 
allows for and requires different follow up to the PheWAS. PheWAS was chosen as an approach 
for a specific reason in each case; each chapter uses PheWAS with a goal in mind. We have 
undertaken PheWAS for many of the same reasons others have before us; to explore pleiotropy, 
identify the functional effects of deleterious variation, and uncover novel associations. 
Importantly, in all cases, PheWAS was used to inform our understanding of the biology 
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underlying genetics. The work presented herein also progresses through different types of 
genetic variation; starting with simple nuclear SNPs, moving to larger deletions, and concluding 
with mitochondrial variation. Each of these variants presents different challenges and 
expectations with PheWAS. While each project was performed as a stand-alone experiment, this 
dissertation aims to draw connections between different analyses to draw qualitative conclusions 
about the method as a whole. Lastly, in the assembled projects, PheWAS is rarely the end point. 
Something is always done after to understand the signal (or lack thereof) seen in the data, to try 
to return to and expand our underlying biological knowledge. 
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This chapter is adapted from a manuscript written with the assistance of C. Michael Stein, 
MBChB; Abiodun Adefurin, MBChB, Msc; Daniel Kurnik, MD; and David C Samuels, PhD. 
 
I.  SEX-SPECIFIC PLEIOTROPY OF THE THR164ILE VARIANT IN THE BETA-2-
ADRENERGIC RECEPTOR 
  
 
Introduction 
 
The beta-2-adrenergic receptor (β2AR ) is one of three subtypes of beta-adrenoceptors, 
βARs28. These G-protein coupled receptors are expressed in a variety of tissues, including the 
heart and bronchial and vascular smooth muscle. The β2AR is also the target of beta2-agonists, 
which act through the receptor to mediate bronchodilation and are used clinically in patients with 
bronchoconstriction, e.g. asthma and chronic obstructive pulmonary disease
29
. There is a great 
variability in response to physiological and pharmacological stimulation or blockade of βARs, 
some of which is due to genetic variation among individuals in genes encoding βARs and their 
signal transduction proteins, including ADRB2, the gene encoding the β2AR. 
 There are three polymorphisms in the coding region of ADRB2 that have been shown to 
affect the functional properties of the receptor both in vivo and in vitro
30
. Two of these variants, 
Arg19Cys and Gln27Glu
31
, form a haplotype and have been studied extensively, particularly in 
relation to asthma, heart failure, and hypertension, but it has been difficult to identify robustly 
associated clinical phenotypes
32
.  The third variant, rs1800888, encodes the relatively uncommon 
ADRB2 Thr164Ile variant that occurs at a frequency of only ~2% in individuals of European 
descent. This ADRB2 variant is of particular interest because it is associated with profoundly 
reduced responses to agonist in vitro and has been associated with a five-fold reduction in 
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sensitivity to β2AR agonist-mediated vasodilation in vivo in humans
33
. Thr164 is located in the 
upper part of transmembrane domain 4, and the nonsynonymous change to Ile has been predicted 
to cause a change in probability of transition of the receptor into the activated state
34,35
. Multiple 
experiments have shown that the presence of Ile at position 164 causes a decrease in receptor 
functionality
36,37
. 
 Despite the strong in vitro and in vivo evidence of functional effects, few studies have 
addressed the functional consequences of the Thr164Ile transition in humans, likely because the 
variant is relatively infrequent. While some studies have reported no association between 
Thr164Ile and hypertension phenotypes
38,39
, these studies had limited power. The two largest 
studies to date found associations of the Ile allele to increased blood pressure, but the effect was 
limited to females
40,41
. The Ile variant at position 164 has also been associated with a lesser 
response to beta2-agonist therapy in patients with asthma
42
 and has been identified as a risk 
allele for chronic obstructive pulmonary disease, though other studies failed to detect these 
risks
43–45
. Moreover, Ile164 has been associated with adverse outcomes in patients with 
congestive heart failure
46
. However, the potential pleiotropy of the variant has not been 
systematically explored.   
As the ADRB2 gene has been associated with multiple phenotypes individually, and 
in vivo studies have shown that the Thr164Ile substitution causes a significant attenuation 
of receptor function, we hypothesized that individuals with this variant would manifest 
with other previously unrecognized clinical phenotypes in a systematic search using a 
PheWAS approach. We therefore conducted a PheWAS to investigate the association of 
Thr164Ile with many potentially interrelated phenotypes in an electronic health record (EHR)-
based cohort.  
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Methods 
 
Study Population 
The study population consisted of adult individuals of European descent as identified by 
a third party. These individuals had both ICD.9 code data and genotyping on the Illumina Human 
Exome Bead Chip available in BioVU, Vanderbilt’s DNA biobank15. The samples with 
genotyping in BioVU are linked to de-identified EHRs.  
 
Genotypes 
Genotypes for SNPs in ADRB2 genotyped on the Illumina Human Exome Bead Chip 
were obtained
47
 and the Thr164Ile allele was extracted. Population frequency was checked 
against 1000 Genomes. All quality control checks of genetic data were done in Plink
48
.  
 
PheWAS 
Using all ICD.9 codes listed for adult patients (patient aged ≥18 years at time of code) 
with genotyping results in our dataset, we performed a phenome-wide association scan. PheWAS 
uses a predefined hierarchy to aggregate ICD.9 codes into PheWAS codes (Phecodes) which are 
then tested for association with a variant of interest
20
. Individuals with 2 or more ICD.9 codes 
that aggregate into a Phecode become a case for that Phecode. Individuals who have only one 
incidence of an ICD.9 code in the Phecode do not meet the definition of either a case or a control 
and are therefore excluded from analysis, as are individuals who could be a control for a code but 
are a case for a related Phecode. All other individuals become a control for that Phecode. Due to 
the exclusions, different Phecodes may have different numbers of total individuals tested.  
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We used logistic regression adjusting for age at last ICD.9 code and sex with an additive 
genetic model to test association of the ADRB2 genotype with Phecodes. The study was 
restricted to individuals of European descent and to Phecodes with 50 or more cases. Limiting 
our analysis to Phecodes with 50 or more cases helped reduce our multiple testing threshold, 
while increasing the chance we would have power to see an association. Hardy-Weinberg 
equilibrium was checked in each regression. As a secondary analysis, we stratified by sex and 
ran the PheWAS in male and female cohorts separately. All sex-stratified PheWAS analyses only 
examined Phecodes with at least 25 cases. Following PheWAS, chi-square and Fisher’s exact 
tests were used to check the allele distribution in cases and controls. The Bonferroni correction 
for our initial PheWAS was 4.08e-05 as 1224 Phecodes were populated with at least 50 cases. In 
the sex-stratified analyses, the level of statistical significance by Bonferroni correction was 
4.06e-05 for females and 4.5e-05 for males. As Phecodes are often correlated, making a 
Bonferroni correction overly stringent, we also applied a 10% False discovery rate (FDR) 
correction to the data. Any biologically relevant signal that met the FDR level of significance 
was explored more deeply using laboratory data and existing literature.  
  
Blood Pressure Analysis 
As we saw an association between Thr164Il4 and Iatrogenic Hypotension in the PheWAS 
analysis we further explored the effect of the Thr164Ile variant on blood pressure. We studied 
blood pressure measurements first in all individuals, and second, in all individuals excluding 
those with the PheWAS code for Iatrogenic Hypotension. Date and time-stamped blood pressure 
measurements were downloaded and quality-controlled by removing any measurements that 
were not numeric, were negative or duplicate, or had incorrectly formatted dates. Any systolic 
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blood pressure measures greater than 300 mmHg and diastolic blood pressure measures greater 
than 240 mmHg or less than 5 mmHg were removed. Two separate blood pressure analyses were 
performed.  
The first analysis was designed to test the previous association with hypertension and to 
see if our association with Iatrogenic Hypotension extended to general hypotension.  Individuals 
with only one blood pressure measurement were removed. Individuals were categorized 
dichotomously as hypertensive if they had at least two measures greater than 140/90 mmHg in 
their record, and hypotensive if at least two measure less than 90/60 mmHg were present in their 
record. The same individual could therefore be categorized as both hypertensive and 
hypotensive.  
We also performed an analysis to test the influence of the Thr164Il variant on non-
dichotomized summary blood pressure measures. Median, 10
th
 percentile, and 90
th
 percentile 
summary measures were calculated for systolic blood pressure, diastolic blood pressure, and 
mean arterial pressure (MAP) using individuals who had more than 10 measures. Mean arterial 
pressure is a measure that combines both systolic and diastolic blood pressure measures 
(Equation 1).  Linear regression for individuals with 10 or more blood pressure measures was 
performed.  
Equation 1: 𝑀𝐴𝑃 = (
1
3
)(𝑆𝐵𝑃 − 𝐷𝐵𝑃) +  𝐷𝐵𝑃  
 
Liver Enzyme Analysis 
 Since one of the Phecodes that passed the FDR in our analysis was Serum Enzyme 
abnormalities, we downloaded laboratory data for the levels of Aspartate transaminase (AST) 
and Alanine transaminase (ALT).  These measures help quantity liver damage and can also 
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differentiate between possible causes. Non-numeric values, duplicate values, and values with an 
incorrect date and time stamp were removed.  We required individuals to have an AST and ALT 
at the same time, so any measures where only one was present were removed. Median, 
minimum, and maximum values of these enzymes were calculated for each individual. The 
AST/ALT ratio was derived, and the median, minimum, and maximum values were obtained for 
each individual.  
As obesity can impact these measures and has been previously associated with the 
The164Ile allele
49
, we also obtained BMI measures and calculated a median BMI for each 
individual.  
 
Statistical Analyses 
All PheWAS analyses were performed using the PheWAS package for R
50
. Dichotomous 
blood pressure measures were analyzed using logistic regression analyses adjusting for median 
age of all blood pressure measures and sex. Summary blood pressure measures were analyzed 
using linear regression adjusting for median age across blood pressure measures and sex. Sex-
stratified analyses for both types of blood pressure measure were performed adjusting for median 
age. Liver enzyme tests were analyzed using linear regression adjusting for median age over 
measures, sex, and BMI. Sex stratified analyses were also performed. All statistical analyses 
were performed using R 3.1.3
51
. 
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Results 
 
 The population for the study of the ADRB2 Thr164Ile variant included 23,854 individuals 
of European descent; the median age at last ICD.9 code was 64 years, and the median number of 
unique ICD.9 codes per person was 52 (Table 1-A).  
 
Table 1-A. Demographic characteristics of the study population. P-values indicate statistical 
significance of comparisons between males and females. 
 All Males  Females  p-value
1
 
n (%) 23,854 10,971 (46%) 12,883 (54%)  
Median age first ICD.9 
code (IQR) 
54.8 (41.7, 66.4) 57.0 (44.8, 67.0) 52.6 (39.1, 64.7) <0.001 
Median age at last code 
ICD.9 (IQR) 
64.0 (51.9, 75.9) 65.3 (54.3, 76.1) 62.7 (49.8, 75.6) <0.001 
Median number of 
PheWAS codes (IQR) 
23 (11, 44) 23 (10, 43) 24 (11, 44) 0.06 
Median number of ICD.9 
codes (IQR) 
52 (27, 90) 51 (25, 90) 53 (28, 90) 0.002 
Thr164Ile Minor Allele 
Frequency 
0.012 0.013 0.011 0.22 
1
P-value shows statistical significance of Wilcoxon rank sum test  or Fisher’s exact test comparing male and 
females 
 
Our initial PheWAS in the whole cohort showed a statistically significant risk effect for 
Thr164Ile with Iatrogenic Hypotension and Serum Enzyme Abnormalities (Figure 1-A, 
Appendix A). The T allele of Thr164Ile was significantly associated with the risk of Iatrogenic 
Hypotension, OR= 4.98 [95% confidence interval (CI) 2.37-10.47]; p=2.25e-05. This Phecode 
had a limited number of case patients (n=56), and 6 of these cases carried the risk allele (Table 
1-B). By contrast, the Phecode for Serum Enzyme Abnormalities had 336 cases, with an odds 
ratio of 2.50 [95% CI, 1.59 - 3.91]; p= 6.5e-05. 
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Figure 1-A. PheWAS Manhattan plot for the PheWAS of Thr164Ile in a mixed sex population of European descent. The red line is the 
Bonferroni correction for the number of tests, and the blue line is our level of suggestive significance (p=0.001). All hits that passed 
the FDR correction were annotated with their PheWAS description
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Table 1-B. Genotype distribution across cases and controls for statistically significant PheWAS 
codes in males and females combined. 
PheWAS Category and Case Status 
Thr164Ile Minor Alleles 
0 1 2 
Iatrogenic Hypotension Cases 50 5 1 
Iatrogenic Hypotension Controls 18664 451 9 
 
Abnormal Serum Enzyme Level Cases 318 16 2 
Abnormal Serum Enzyme Level Controls 18088 432 6 
 
After sex stratification, no Phecodes were significant in males alone. Two Phecodes, 
Iatrogenic Hypotension and Hypothyroidism, were significant at the level of the Bonferroni 
correction (p-value of 4.06e-05), and an additional three were significant by FDR in females 
(Figure 1-B, Appendix B). Iatrogenic Hypotension remained significant (OR= 7.50 [95%CI, 
3.25-17.30]; p=2.26e-06), but the case number was low in females only as was the number with a 
minor allele (Table 1-C). Acquired Hypothyroidism was the second most significant hit (OR= 
4.64 [95% CI, 2.35-9.15]; p=9.57e-06). Abnormal Serum Enzyme Levels also remained 
significant in females alone (OR=3.14 [95% CI, 1.79-5.50]; p=6.57e-05), followed by Drug-
Resistant Infection (OR= 2.91 [95% CI, 1.70-4.97]; p=9.10e-05). The Phecode for Ingrowing 
Nail was also significant by FDR, but we did not explore this code further. While Acquired 
Hypothyroidism was not significant at a Bonferroni corrected level or by FDR in the whole set it 
was beyond the level of suggested significance of p< 0.001 (Figure 1-C). The signal seen in 
women with Drug-Resistant Infection was present at a much attenuated level of significance in 
the whole cohort.  None of our other expected signals were significant in all individuals or 
women alone (Appendix C).
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Figure 1-B. PheWAS Manhattan for the PheWAS of Thr164Ile in a female-only population of European descent. The red line is the 
Bonferroni correction for the number of tests, and the blue line is our level of suggestive significance (p=0.001). All hits that passed 
the FDR correction were annotated with their PheWAS description. 
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Figure 1-C. Forest plot of PheWAS hits for Thr164Ile is visible in all individuals and in females only.
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Table 1-C. Genotype distribution across cases and controls for statistically significant PheWAS 
codes in females only. 
PheWAS Category and Case Status 
Thr164Ile Minor Alleles 
0 1 2 
Iatrogenic Hypotension Cases 27 4 1 
Iatrogenic Hypotension Controls 10337 263 4 
 
Acquired Hypothyroidism Cases 73 7 1 
Acquired Hypothyroidism Controls 8662 214 2 
 
Drug Resistant Infection Cases 179 12 1 
Drug Resistant Infection Controls 10504 258 4 
 
Abnormal Serum Enzyme Level Cases 156 9 2 
Abnormal Serum Enzyme Level Controls 9909 246 3 
 
  
22,314 of our study subjects had at least two blood pressure measures, including 12024 
females and 10290 males. The median [IQR] number of blood pressure readings in study 
subjects was 154.0[47.0, 673.8]. Analysis of blood pressure measurements using all individuals 
found that Thr164Ile was associated with hypotension (at least two measure less than 90/60 
mmHg) in males and females combined (OR=1.21 [95% CI, 1.01-1.44]) after adjustment for sex 
and median age, and in females alone after adjustment for median age (OR=1.29 [95% CI,1.02-
1.64]).  Sex and age were also significant predictors in several of the regressions; male sex and 
increasing age were associated with both hypertension and hypotension (Table 1-D). After the 55 
Iatrogenic Hypotension cases in our blood pressure analysis were removed, the association 
between Thr164Ile and hypotension in all individuals, and in females, decreased and was no 
longer significant at the 0.05 level, and the odds ratio weakened slightly compared to when the 
Iatrogenic Hypotension cases were included (Table 1-E). 
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Table 1-D. Association of Thr164Ile with hypotension and hypertension in all individuals with a 
minimum of two blood pressure measures. Odds ratio (95% CI) and p-values are shown for the 
importance of each predictor in the regression. Individuals were classified as hypotensive if they 
had two measures less than 90/60 and hypertensive if they had two measures over 140/90.  
Median age was calculated using the ages at all blood pressure measures in the record. 
 
All                              
(n=22,314) 
Males                         
(n=10,290) 
Females                    
(n=12,024) 
 
Hypotensive 
OR (95% CI) 
Hypertensive  
OR (95% CI) 
Hypotensive  
OR (95% CI) 
Hypertensive  
OR (95% CI) 
Hypotensive  
OR (95% CI) 
Hypertensive  
OR (95% CI) 
Thr164Ile 
Allele 
1.21          
(1.01, 1.44) 
p=0.039 
1.13        
(0.96, 1.34) 
p=0.154 
1.11         
(0.85, 1.45) 
p=0.449 
1.27        
(0.98, 1.65) 
p=0.0764 
1.29        
(1.02, 1.64) 
p=0.034 
1.04        
(0.83, 1.30) 
p=0.761 
Median 
Age 
1.011      
(1.009, 1.013) 
p<0.001 
1.012        
(1.011, 1.014) 
p<0.001 
1.015       
(1.013, 1.018) 
p<0.001 
1.003    
(1.000, 1.005) 
p<0.001 
1.007     
(1.005, 1.009) 
p<0.001 
1.02        
(1.017, 1.021) 
p<0.001 
Sex==M 
1.10        
(1.01, 1.17) 
p<0.001 
1.36        
(1.29, 1.44) 
p=0.001 
- - - - 
 
 
 
 
Table 1-E. Association of Thr164Ile with hypotension and hypertension in individuals without 
the Iatrogenic Hypotension Phecode and a minimum of two blood pressure measures. Odds ratio 
(95% CI) and p-values are shown for the importance of each predictor in the regression. 
Individuals were classified as hypotensive if they had two measures less than 90/60 and 
hypertensive if they had two measures over 140/90.  Median age was calculated using the ages at 
all blood pressure measures in the record. 
 
All                              
(n=22,259) 
Males 
(n=10,266) 
Females                    
(n=11,993) 
 
Hypotensive 
OR (95% CI) 
Hypertensive 
OR (95% CI) 
Hypotensive 
OR (95% CI) 
Hypertensive 
OR (95% CI) 
Hypotensive 
OR (95% CI) 
Hypertensive 
OR (95% CI) 
Thr164Il
e Allele 
1.17        
(0.98, 1.40)  
p=0.091 
1.12         
(0.94, 1.33) 
p=0.203 
1.10        
(0.84, 1.44)  
p=0.475 
1.26          
(0.97, 1.64) 
p=0.083 
1.23        
(0.96, 1.57)  
p=0.096 
1.02         
(0.81, 1.28)  
p=0.897 
Median 
Age 
1.011       
(1.009, 1.013)   
p<0.001 
1.012         
(1.011, 1.014)   
p<0.001 
1.016      
(1.013, 1.018)   
p<0.001 
1.002       
(1.000, 1.005)   
p<0.031 
1.007     
(1.004, 1.09)  
p<0.001 
1.019         
(1.017, 1.021)   
p<0.001 
Sex==M 
1.10        
(1.04, 1.17) 
p<0.001 
1.36         
(1.29, 1.44) 
p<0.001 
- - - - 
 
 
 
 23 
In our analysis of summary blood pressure measures, the Thr164Ile variant was not 
significantly associated with median systolic blood pressure, median diastolic blood pressure, or 
median MAP in both males and females combined. In the female only analysis, none of the 
measure were significantly associated with the variant, and while Thr164Ile was marginally 
(p<0.1) associated with increased median systolic blood pressure in males, none of the tests were 
significant at the p=0.05 threshold (Table 1-F).  The same held true for our tests of the variant as 
a predictor of 10
th
 percentile BP (Table 1-G). When looking at the relationship between the 90
th 
 
percentile BP measures, we saw that the Ile allele was associated with increased systolic 
measures in males only (p=0.04), and was nearly statistically significant but did not reach p=0.05 
for MAP (Table 1-H). The variant was not significant for any measures in either all individuals 
or females alone.  
In order to determine if the pattern of PheWAS signals represented several discrete 
phenotypes or sub-phenotypes of a single condition, we identified how many females were cases 
for multiple of our top Phecodes. In females, individuals (including those carrying the Thr164Ile 
variant) who were cases for one of the top Phecode hits were unlikely to be cases for any of the 
other Phecode hits that passed significance thresholds (Figure 1-D-a), indicating that these are 
distinct and pleiotropic genotype-phenotype associations.  
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Table 1-F. Regression coefficients from linear regression for a mixed population, males, and females with median systolic blood 
pressure, diastolic blood pressure, and mean arterial pressure. 
 
 
 
 
 
 
 
 
All 
(n=21,339) 
Males 
(n=9,854) 
Females 
(n=11,485) 
 
Median  
Systolic BP 
Beta  
(95%CI) 
Median 
Diastolic BP  
Beta 
(95%CI) 
Median  
MAP  
Beta  
(95%CI) 
Median 
Systolic BP 
Beta 
(95%CI) 
Median 
Diastolic BP  
Beta  
(95%CI) 
Median  
MAP 
Beta 
(95%CI) 
Median  
Systolic BP   
Beta 
(95%CI) 
Median 
Diastolic BP 
Beta 
(95%CI) 
Median  
MAP  
 Beta 
(95%CI) 
Thr164Ile 
Allele 
0.13 
(-0.95, 1.21) 
p=0.82 
-0.12 
(-0.85, 0.61) 
p=0.75 
0.03 
(-0.72, 0.77) 
p=0.95 
1.38 
(-0.25, 3.01) 
p=0.0961 
0.61 
(-0.49, 1.71) 
p=0.28 
0.91 
(-0.22, 2.04) 
p=0.12 
-1.00 
(-2.42, 0.42) 
p=0.17 
-0.66 
(-1.69, 0.23) 
p=0.14 
-0.74 
(-1.74, 0.25) 
p=0.14 
Median 
Age 
0.20 
(0.19, 0.21) 
p<0.001 
-0.14 
(-0.14, -0.13) 
p<0.001 
-0.01 
(-0.03, -0.02) 
p<0.001 
0.07 
(0.07, 0.10) 
p<0.001 
-0.16 
(-0.17, -0.15) 
p<0.001 
-0.08 
(-0.09, -0.06) 
p<0.001 
0.28 
(0.27, 0.39) 
p<0.001 
-0.12 
(-0.13, -0.11) 
p<0.001 
0.01 
(0.01, 0.02) 
p=0.002 
Sex==M 
1.03 
(0.68, 1.37) 
p<0.001 
2.21 
(1.97, 2.44) 
p<0.001 
1.81 
(1.57, 2.05) 
p<0.001 
- - - - - - 
 25 
Table 1-G. Regression coefficients from linear regression for a mixed population, males, and females with 10th percentile systolic 
blood pressure, diastolic blood pressure, and mean arterial pressure. 
 
All 
(n=21,339) 
Males 
(n=9,854) 
Females 
(n=11,485) 
 
10%  
Systolic BP 
Beta (95%CI) 
10% 
Diastolic BP 
Beta 
(95%CI) 
10%   
MAP  
Beta 
(95%CI) 
10%  
Systolic BP 
Beta 
(95%CI) 
10% 
Diastolic BP 
Beta 
(95%CI) 
10%  
MAP  
Beta 
(95%CI) 
10%  
Systolic BP 
Beta 
(95%CI) 
10% 
Diastolic BP 
Beta 
(95%CI) 
10%   
MAP  
Beta 
(95%CI) 
Thr164Ile 
Allele 
-0.13 
(-1.17, 0.91) 
p=0.81 
-0.03 
(-1.07, 0.46) 
p=0.44 
-0.12 
(-0.87, 0.63) 
p=0.76 
0.38 
(-1.21, 1.97) 
p=0.64 
0.24 
(-0.92, 1.41) 
p=0.68 
0.48 
(-0.67, 1.62) 
p=0.41 
-0.64 
(-1.99, 0.72) 
p=0.36 
-0.76 
(-1.77, 0.26) 
p=0.14 
-0.64 
(-1.62, 0.35) 
p=0.21 
Median 
Age 
0.08 
(0.07, 0.09) 
p<0.001 
-0.14 
(-0.15, -0.14) 
p<0.001 
-0.05 
(-0.06, -0.05) 
p<0.001 
-0.01 
(-0.03, 1.90) 
p=0.09 
-0.16 
(-0.17, -0.14) 
p<0.001 
-0.10 
(-0.10, -0.08) 
p<0.001 
0.14 
(0.13, 0.16) 
p<0.001 
-0.14 
(-0.15, -0.13) 
p<0.001 
-0.02 
(-0.03, -0.02) 
p<0.001 
Sex==M 
0.80 
(0.46, 1.13) 
p<0.001 
2.08 
(1.84, 2.33) 
p<0.001 
1.67 
(1.43, 1.91) 
p<0.001 
- - - - - - 
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Table 1-H. Regression coefficients from linear regression for a mixed population, males, and females with 90th percentile systolic 
blood pressure, diastolic blood pressure, and mean arterial pressure. 
 
All 
(n=21,339) 
Males 
(n=9,854) 
Females 
(n=11,485) 
 
90% 
Systolic BP 
Beta 
(95%CI) 
90% 
Diastolic BP 
Beta 
(95%CI) 
90% 
MAP  
Beta 
(95%CI) 
90%  
Systolic BP  
Beta 
(95%CI) 
90% 
Diastolic BP 
Beta 
(95%CI) 
90% 
MAP  
Beta 
(95%CI) 
90%  
Systolic BP 
Beta 
(95%CI) 
90% 
Diastolic BP 
Beta 
(95%CI) 
90% 
MAP  
Beta 
(95%CI) 
Thr164Ile 
Allele 
0.39 
(-0.89, 1.67) 
p=0.55 
0.07 
(-0.66, 0.81) 
p=0.85 
0.14 
(-0.66, 0.94) 
p=0.74 
2.00 
(0.10, 3.89) 
p=0.04 
0.80 
(-0.32, 1.92) 
p=0.16 
1.14 
(-0.07, 2.34) 
p=0.07 
-1.05 
(-2.76, 0.67) 
p=0.23 
-0.55 
(-1.52, 0.41) 
p=0.26 
-0.73 
(-1.80, 0.33) 
p=0.18 
Median 
Age 
0.33 
(0.32, 0.34) 
p<0.001 
-0.09 
(-0.10, -0.09) 
p<0.001 
0.03 
(0.02, 0.04) 
p<0.001 
1.95 
(0.18, 0.21) 
p<0.001 
-0.14 
(-0.15, -0.13) 
p<0.001 
-0.04 
(-0.05, -0.03) 
p<0.001 
0.43 
(-0.41, 0.44) 
p<0.001 
-0.06 
(-0.07, -0.06) 
p<0.001 
0.08 (0.07, 
0.09) 
p<0.001 
Sex==M 
1.02 
(0.06, 1.43) 
p<0.001 
2.00 
(1.76, 2.23) 
p<0.001 
1.70 
(1.45, 1.96) 
p<0.001 
- - - - - - 
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Figure 1-D. Venn diagram of the overlap of case individuals for PheWAS codes. a) Codes that 
were significant in either the analysis of all individuals or in females only were tested for overlap 
in females. b) The overlap of individuals coded for Drug-resistant Infection, Pneumonia, and 
Poisoning by Other Anti-Invectives in the female only population. 
 
 
In PheWAS hits that passed the p-value threshold of 0.001 for suggestive significance in 
females, three codes (Drug-resistant Infection, Poisoning by Other Anti-infectives, and 
Pneumonia), were related to infection. Of females who had the Phecode for Drug-resistant 
Infection, 58% also had the Phecode for pneumonia (Figure 1-D-b). We also observed the 
Phecode for Poisoning by Other Anti-infectives, but the women with this code were largely 
distinct from those coded for Drug-resistant Infection. The Phecode for Drug-Resistant Infection 
is made up of 19 ICD-9 codes focused exclusively on drug resistance. The Phecode for 
Pneumonia comprised of 67 distinct codes (Appendix D). Most of these codes are immediately 
related to pneumonia, though some relate to congestion or difficulty breathing when an infection 
may be present. No ICD.9 codes are shared between the Phecode for Drug-resistant Infection and 
the Phecode for Pneumonia.  
a b 
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 Our analysis of the liver function test laboratory values produced no significant 
associations after adjustment for BMI.  The Thr164Ile allele was not significantly associated 
with median AST (Beta [95% CI] = -0.94[-2.48,0.60],p=0.23) , median ALT ( -1.26[-2.96,0.44], 
p=0.15) or median AST/ALT ratio (0.02[-0.02, 0.06], p=0.31) after adjustment for BMI  in all 
individuals. In females, the median AST/ALT ratio was not associated with the Thr164Ile allele 
(0.04[-0.01, 0.09], p=0.14), nor was median AST (-0.83 [-2.77, 1.11], p=0.40), but median ALT 
was associated (-2.09 [-4.11, -0.06], p=0.044) with each copy of the Ile allele resulting in 
decreasing ALT. BMI was the most significant predictor of the liver enzymes, and was also 
moderately associated with the Thr164Ile allele.  
 
Discussion 
 
The primary PheWAS association for the Thr164Ile variant in ADRB2 was the code for 
Iatrogenic Hypotension. This association with hypotension was the opposite of what would be 
expected given the previous reports of an association with hypertension in other studies
40,41
  and 
given the observation that the variant was associated with decreased agonist-induced 
vasodilation in translational studies
33
.  
Several reasons could explain our finding. Iatrogenic Hypotension describes a clinical 
scenario where a medical intervention inadvertently results in low blood pressure, i.e. an 
exaggerated hypotensive response to a medication or intervention. The population studied was a 
hospital-based cohort, and patients thus underwent medical interventions and received new 
medications; manual review of the records of the cases with a PheWAS diagnosis of Iatrogenic 
Hypotension revealed that 33 of 56 had undergone surgery shortly before the ICD.9 code was 
 29 
entered into their record. The biology of the β2AR suggests a mechanism whereby individuals 
with the Thr164Ile variant could be at increased risk for hypotension in such circumstances 
despite having impaired β2AR-mediated vasodilation and thus a propensity towards 
hypertension. The β2AR, in addition to mediating vasodilation, also increases heart rate and 
cardiac contraction, and thus cardiac output, a key determinant of blood pressure. Healthy 
Thr164Ile carriers have decreased chronotropic and inotropic responses to beta2-agonists
52
, and 
this attenuated cardiac response was even more pronounced in patients with heart failure
53
.  It is 
therefore possible that individuals with attenuated β2AR-mediated signal transduction may 
become hypotensive in a postoperative setting where compensatory sympathetic stimulation and 
increased plasma catecholamine concentrations are critical to maintain blood pressure by 
increasing heart rate and contractility and thus cardiac output.   
 Consistent with the PheWAS code of Iatrogenic Hypotension, our analysis of all the 
blood pressure readings recorded also indicated that individuals with the Thr164Ile variant (in 
analyses that included and excluded those with the Iatrogenic Hypotension code) had increased 
odds of being hypotensive at some point in their medical record.  Interestingly, this result was 
not visible when the median, 90
th
, and 10
th
 percentile blood pressure measures were used. While 
other studies have shown that carriers of the variant are more likely to be hypertensive, that was 
not the case in this study. However, in males there was a trend in that direction, and in our 
summary analysis, the variant was associated with increased 90
th
 percentile measures in men. 
Many of the blood pressure measures in our dataset were not resting blood pressure measures, 
but rather measures obtained during a hospital stay or other intervention. Thus, the effects of 
stressors such as medications and illness may be magnified under these circumstances.  
 30 
 We observed the significant genotype-hypotension association in all individuals and in 
females  only, consistent with other large studies of the Thr164Ile variant that found an effect on 
hypertension in females only
40,41
. As our study was conducted in an EHR dataset, it is possible 
that there was a difference in coding between males and females for certain traits, but as the case 
distribution was similar in both sexes for our primary hits, it is more plausible that there is a 
fundamental biological difference between the sexes in the effect of the variant. This is in 
keeping with the observation that there are differences among sexes in cardiac physiology, and 
women are more dependent than men on an increase in heart rate to maintain cardiac output 
under conditions of stress
54
. Therefore, an inability to increase heart rate to maintain cardiac 
output in Thr164Ile individuals under conditions of stress would be more likely to manifest as 
hypotension in women.        
The lack of overlap of phenotypes in the same individuals suggests that Thr164Ile is 
associated with multiple distinct phenotypes. Alternatively, the different phenotypes could be 
related and coexist in the same patient, with only one being prominent enough to be listed as ICD 
diagnosis by the physician. 
 The code for Serum Enzyme Abnormalities encompassed only ICD.9 code 790.5 for 
“Other Nonspecific Abnormal Serum Enzyme Levels”, representing predominantly an increase 
in serum liver enzymes. The increase in liver enzymes associated with Thr164Ile may be related 
to altered effects of catecholamines on liver cells
55
 or effects on fat metabolism. Given the 
change in effect we saw after adjusting for BMI, it is also possible that the effect is related to 
BMI. The β2AR mediates lipolysis, and adipocytes from humans heterozygous for the Ile164 
variant had a markedly decreased sensitivity to lipolysis induced by a beta-agonist
56
. Moreover, 
Ile164 was associated with obesity in population studies
49
. Obesity is the main risk factor for 
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non-alcoholic fatty liver disease, a common cause of elevated liver enzyme levels. Indeed, 
ADRB2 variants have previously been associated with liver enzyme levels, and a link to non-
alcoholic fatty liver disease was postulated
57
. 
 
The association of Thr164Ile with Acquired Hypothyroidism in females was unexpected 
but not biologically implausible. Thyroid hormone contributes to the regulation of βAR 
expression and has been associated with hypertension and other cardiovascular phenotypes
58–61
. 
Deficiency of thyroid hormone reduces responsiveness to catecholamines due to reduced βAR 
expression
62
; thus, it is possible that the presence of an ADRB2 variant associated with reduced 
function could magnify the effects of hypothyroidism, facilitating its diagnosis.  
The women who had the PheWAS code for Drug-resistant Infection overlapped 
substantially (58%) with those who were coded for Pneumonia. The Thr164Ile variant has been 
associated with several pulmonary phenotypes, including impaired bronchoconstriction, reduced 
lung function, and chronic obstructive pulmonary disease (COPD)
43
, which are risk factors for 
recurrent pulmonary infections, reduced clearance of infections, and thus antibiotic resistance. 
Moreover, patients with underlying pulmonary diseases such as COPD could be more likely to 
be assigned a diagnosis of pneumonia. Alternatively, cross-talk between the immune and 
adrenergic systems through the β2AR may be implicated
63
. 
The potential mechanisms underlying the sex-specificity of the PheWAS findings are of 
interest.  One possibility is that coding practices among health care providers differ for men and 
women.  However, more likely is that β2AR responses are affected by sex, and there are many 
examples of such sex-related differences in other settings. For example, differences between men 
and women in the contribution of β2AR-mediated responses have been noted for blood pressure 
regulation
64
, cutaneous 
65
 and forearm blood flow
66,67
, neutrophil function
68
, and the anabolic 
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effects of an agonist
69
, or among pre- and post-menopausal women. It is possible similar 
mechanism pertain in the setting of illness.   
 In conclusion, our study has shown that Thr164Ile has pleiotropic effects, and carriers 
are more likely to be assigned certain diagnosis codes by their physicians. Our PheWAS study, 
while testing for association with imperfectly phenotyped case and control groups, allowed us to 
identify genotype-Phecode associations that were plausible given the multiple physiological 
functions of the β2AR. Replication in carefully phenotyped populations will be important for 
validating these associations.
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II.  THE APOBEC3G HIS186ARG VARIANT IMPACTS HUMORAL IMMUNITY IN 
CHILDREN 
  
Introduction 
 
The apolipoprotein B mRNA-editing catalytic polypeptide (APOBEC) family is a group 
of cytidine deaminases that were initially discovered due to the ability of APOBEC3G (A3G) to 
block the replication of Human Immunodeficiency Virus Type 1 (HIV-1)
70
. The APOBEC3 sub-
family is a group of 7 proteins (A3A-A3C, A3DE, A3F-H) encoded on chromosome 22. As 
cytidine deaminases, the members of this family mediate the change from C to T in single 
stranded DNA
71
.  The A3s are thought to have evolved from APOBEC1, and the gene 
duplication events leading to the family are thought to have occurred during the expansion of the 
primate branch as a means of countering the exogenous and endogenous retroviruses
72
. A3G in 
particular has been subject to strong positive selection throughout primate evolution
73
.  The 
APOBEC3s are known to function against exogenous retroviruses and human endogenous 
retroviruses, both through deamination dependent and deamination independent functions.  
A3G and its variation has been thoroughly investigated for its effect in HIV. The A3G 
His186Arg variant is located in exon 4 of the APOBEC3G gene
74
. While this region of the 
protein in not directly involved in deamination, it is thought to be important for RNA binding 
which is involved in several deaminase independent functions and sliding along genetic material 
to promote deamination
75
. Some studies have shown that individuals of African descent with the 
A3G His186Arg variant progress from HIV to AIDs more quickly, but this effect of the variant 
does not seem present in individuals of European descent
74,76,77
. Biochemically, there is 
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increasing evidence that A3G proteins containing the His186Arg change exhibit less antiviral 
activity than wildtype A3G
78
. The effect of the His186Arg variant in populations infected with 
Hepatitis-B virus (HBV) has also been explored, but no effect was seen
79
.  While the global 
allele frequency of A3G His186Arg is 14.6%, the variant is present at a frequency of around 3% 
in populations of European descent
80
. Despite the relatively common global occurrence of this 
variant, it has not been widely explored outside of the context of viral infection. 
Given the limited knowledge of the A3H His186Arg variant and the conflicting 
reports of it importance in the context of HIV1 infection, we hypothesized that it was likely 
this variant manifested in one or more clinically relevant phenotypes in a hospital derived 
cohort. We specifically expected phenotypes of viral infection or other innate immune 
responses. To test this hypothesis, we performed a PheWAS in an EHR based dataset, exploring 
the impact of the A3G His186Arg variant on multiple clinically relevant phenotypes.  
 
Methods 
 
Study Population 
The study population consisted of third-party identified white individuals with both ICD.9 code 
data and genotyping available on the Illumina Human Exome Bead Chip available in BioVU.  
  
Genotypes 
Genotypes for SNPs in A3G genotyped on the Illumina Human Exome Bead Chip were 
obtained. rs8177832, the SNP for His186Arg, was additively encoded and checked against 
published minor allele frequencies
80
. All quality control checks of genetic data were done in 
Plink 
48
.  
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PheWAS Aggregation and Regression 
A record of all ICD-9 codes with date stamps were obtained for all individuals with genotyping. 
These were aggregated using a predefined hierarchy into PheWAS codes (Phecodes) as 
described in the Introduction. Briefly, individuals with 2 or more instances of any ICD-9 code 
that map to a Phecode become cases for that Phecode. Individuals who never have any instance 
of the ICD-9 codes within a Phecode become a control for that code. Individuals who have a 
single occurrence of one ICD-9 code within a Phecode become an “NA” and are excluded from 
analysis for that Phecode. Individuals can also be excluded from analysis if by aggregation they 
would be a control for a given Phecode, but are a case for a highly related Phecode.  This 
exclusion only removes potential controls, never potential cases. ICD-9 codes that occur more 
than once on the same day in a patient’s record are collapsed to one occurrence.  Phecodes are 
then tested for association with a variant of interest.  
Our initial PheWAS used logistic regression adjusting for age at last ICD-9 code in the 
record, and sex. We also performed a second PheWAS limiting our dataset to individuals who 
never reached the age of 20 in their ICD-9 based record. This logistic regression was also 
adjusted for age and sex. In PheWAS tests using all individuals, only Phecodes with at least 50 
cases were tested. In age stratified PheWAS tests, Phecodes with at least 25 cases were tested. 
 
ICD-9 Code Specific Analyses 
Following PheWAS, we performed a series of logistic regressions using the ICD-9 codes within 
the Humoral Immunity Phecode as the outcome. The ICD-9 code records of all individuals were 
evaluated, and two instances of a specific ICD-9 code were considered a case for that ICD-9 
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code. Regressions performed separately in all individuals and individuals under 20, and were 
adjusted for first age at ICD-9 code and sex. Venn diagrams were made with Venny 
81
. 
 
CPT Code Analysis 
CPT codes for immune globulin infusions (82784) were obtained for white individuals 
with genotyping in our dataset. The number of codes each individual had were calculated. The 
minor allele frequency of His186Arg was calculated in individuals with at least one “82784” 
CPT code, and compared to the minor allele frequency in the whole population. A Wilcoxon 
rank sum test was used to see if the number of CPT codes on distinct days was different between 
the carriers and non-carriers of the His186Arg allele. The population overlap between 
individuals with the “82784” CPT code and those with the Deficiency of Humoral Immunity 
Phecode was also calculated.   
 
Laboratory Value Analysis 
Immunoglobulin G (IgG) laboratory values from the IgG Quantitative (IgG-Q) test were 
downloaded for individuals in the set.  IgG values were quality controlled to remove non-
numeric values and were then normalized using the age of the individual at the time of their 
measure and reference information from the Vanderbilt Pathology Laboratory Services (Appendix 
H). 
Maximum, median, and minimum values were calculated using both raw and normalized 
IgG values all individuals with two or more measures. Wilcoxon rank sum tests were used to 
examine if these summary measures of IgG were different between homozygous reference 
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individuals and carriers of the His186Arg variant. Individuals were also stratified based on age at 
the time of measure, and adults and children were analyzed separately.  
 
Results 
 
27547 individuals were in our PheWAS dataset. 3,837 were younger than 20 at the last 
ICD-9 code in their record, and 23,710 had an age at last code greater than 20 (Table 2-A). 
46.7% of the study individuals were male. The allele frequency of the His186Arg variant was not 
significantly different between individuals with an age at last code greater than 20 and an age at 
last code of less than 20, though it was trending towards significance.  
 
Table 2-A. Demographics of the PheWAS analysis set combined and separated by age at last 
ICD-9 record. 
 
 
Our initial PheWAS tested 1215 Phecodes. A single Phecode, Deficiency of Humoral 
Immunity (Odds ratio (OR) = 2.93 [95% Confidence interval (CI) 1.83 -4.68]; p= 7.01E-06), 
passed the Bonferroni level of statistical significance (4.1e-05) (Figure 2-A). There were 108  
 All 
Age at Last Code 
<20 
Age at Last Code 
>=20 
p-value 
N 27547 3837 23710 - 
Male (%M) 12865 (46.7%) 1981 (51.6%) 10884 (45.9%) 0.004 
Median Age First ICD-9 Code 
in Record (IQR) 
51.4 (32.4, 64.7) 2.1 (0.2, 7.0) 55.2 (42.5, 66.6) <2.2e-16 
Median Age Last ICD-9 Code 
in Record (IQR) 
60.7 (42.1, 73.6) 11.7 (6.9, 15.6) 64.1 (52.4, 75.8) <2.2e-16 
Deficiency of Humoral 
Immunity Cases (%) 
108 27 81 0.002 
His186Arg Allele Frequency 0.031 0.035 0.030 0.07 
 38 
 
Figure 2-A. PheWAS manhattan plot showing the association of the Phecode for Deficiency of Humoral Immunity and the A3G 
His186Arg variant. Red line indicates Bonferroni correction and blue line indicates level of suggestive significance.
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cases for Deficiency of Humoral Immunity, including 19 with the A3G 186R allele (Table 2-B). 
Only one other Phecode, Hallucinations, passed the level of suggestive significance (p=0.001) 
(Appendix E). 
 
Table 2-B. Genotype distribution in Deficiency of Humoral Immunity cases and controls for 
individuals of all ages. 
PheWAS Category and Case Status 
His186Arg Minor Alleles 
0 1 2 
Deficiency of Humoral Immunity Cases 89 19 0 
Deficiency of Humoral Immunity Controls 23668 1463 32 
 
 
Of the 9 ICD-9 codes (Appendix G) that comprised the Deficiency of Humoral Immunity 
PheWAS code only 2 of which were present twice in at least 5 individuals in our dataset. The 
ICD-9 code 279.00 contributes that largest signal, but that there is a second signal from 279.06 
(Table 2-C). These signals contribute similar ORs but have substantially different p-values and 
case sizes. The signal from the union of these two groups is weaker than the signal from just 
279.00 alone, indicating that 279.00 is the primary driver of our association (Figure 1-A). 
 
Table 2-C. Association of His186Arg variant with individuals who have two or more incidences 
of the 279.00, 279.06, and 279.00 or 279.06 ICD-9 codes combined. 
ICD-9 Code OR (95% CI) p-value Case Individuals Control Individuals 
279.06 3.37(1.47, 7.77) 0.004274 30 27353 
279.00 3.50 (2.12, 5.77) 8.66E-07 81 27353 
279.00, 279.06, or 
279.00 and 279.06 in 
combination 
3.21 (1.98, 5.21) 2.28E-06 97 27353 
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Figure 2-B. Venn diagram of distribution of His186Arg minor alleles in individuals with two 
incidences of the 279.00 ICD-9 code or the 279.06 ICD-9 code. 
 
 
 
We then evaluated the median age at which people are first coded with 279.00. The 
median age at first code of heterozygotes (8.9 yrs) was significantly different, p=0.03, then the 
median age at first code of homozygous dominants (50.55 yrs) (Figure 2-C). The number of 
incidences of the 279.00 ICD-9 code in the two groups were not significantly different.  
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Figure 2-C. Histogram of the age at which Deficiency of Humoral Immunity individuals first 
have the 279.00 ICD-9 code in their record. 
 
 
As the ICD-9 specific signal appeared to be driven by children, we wanted to see if other 
signals could be seen in a PheWAS of children alone. In individuals who never passed the age of 
20 in their ICD-9 record, Deficiency of Humoral Immunity was again the only statistically 
significant hit, with an OR of 5.55 [95% CI 2.62 -11.76] and a p-value of 7.7E-06 (Figure 2-D, 
Appendix F). Our number of cases substantially decreased to 27 (9 with the 186R allele) 
reducing our power (Table 2-D), but we saw a stronger effect size in the younger individuals. 
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Figure 2-D. PheWAS manhattan plot for the A3G His186Arg variant in individuals under the age of 20. Red line indicates Bonferroni 
correction and blue line indicates level of suggestive significance.
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Table 2-D. Genotype distribution in Deficiency of Humoral Immunity cases and controls for 
individuals under the age of 20 at their last ICD-9 code entry. 
PheWAS Category and Case Status 
His186Arg Minor Alleles 
0 1 2 
Deficiency of Humoral Immunity Cases 18 9 0 
Deficiency of Humoral Immunity Controls 3295 229 6 
 
 
 Even when we further decreased the age cut off for individuals tested beyond an age at 
last code of 20, we still saw the association in the PheWAS. While we very quickly ran out of 
power to see a signal due to decreasing numbers of individuals with the His186Arg allele, even 
when we subset our data to those under the age of 8, the influence of the variant on Deficiencies 
of Humoral Immunity remained substantial (Figure 2-E). All of our younger groups showed an 
odds ratio of between 5.5 and 7.8, much stronger than in the whole population. 
3544 individuals in our dataset had an ‘82784’ CPT code in their record. The number of 
CPT codes for infusion was not different between carriers and non-carriers of the His186Arg 
allele (p=0.12). We also looked to see if the allele frequency in those with the CPT codes was 
higher than expected, but at 0.032 it was not significantly different than the allele frequency seen 
in the whole population used for our PheWAS. Almost all individuals who were PheWAS cases 
for Deficiency of Humoral Immunity (100 out of 108) had a ‘82784’ CPT code in their record, 
including all 19 carriers of the 186Arg allele (Figure 2-F). 
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Figure 2-E. Forest plot for the association of His186Arg in the entire population, a population with an age at last code less than 30, a 
population with an age at last code under 20, 16, 12, and 8. Odd ratio (OR), p-value, and the number of cases in each of the PheWAS 
associations are shown.
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Figure 2-F. Venn diagram of overlap between individuals with an ‘82784’ CPT code for 
Gammaglobulin Influsion and those who were cases for the Deficiency of Humoral Immunity 
PheWAS code. Distribution of individuals who are carriers for the His186Arg allele are also 
shown. 
 
 
865 individuals with genotype data available had more than one IGG measure in their 
record. 198 of these were under the age of 19 at the time of their measure. None of the IGG 
summary measures for either the normalized or raw data were significantly different by genotype 
at the p=0.05 level. None of the summary measures was significant after stratification by age at 
test.
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Discussion 
 
In our analysis, the His186Arg variant in APOBEC3G was associated with the PheWAS 
code for Deficiency of Humoral Immunity. As our a priori hypothesis was that the variant would 
be associated with an immune related phenotype, this was not entirely unexpected, but an 
association that came mostly from young individuals was completely unexpected. We also 
anticipated more of an innate immune phenotype, rather than the adaptive immune phenotype of 
humoral immunity. 
There is no established mechanism for how A3G might affect levels of immunoglobulins. 
A3G is widely expressed in hematopoietic cells, including B-cells, T-cells, and myeloid 
cells
82
.  In these cells A3G protein localizes to the cytoplasm where it performs one of two 
functions; protect against exogenous retroviruses or prevent endogenous retroelements from 
completing retrotranscription and reintegrating into the genome. Within the cytoplasm, A3G 
exists in two forms called high molecular mass (HMM) A3G and low molecular mass (LMM) 
A3G. HMM A3G is A3G bound with ribonuclear protein complexes called P-bodies
83
. HMM 
A3G is less enzymatically active and functions to oppose retrotransposition of endogenous 
retroelements. Endogenous A3G expressed in H9 T-cells and mitogen-activated CD-4 T cells 
exists in a HMM state. The assembly into complexes is thought to be one mechanism of 
regulating the possibly mutagenic properties of A3G. By contrast, LMM A3G is much more 
enzymatically active, and is necessary for activity against exogenous retroviruses
83
. Interestingly, 
some RNA binding proteins involved in cell fate determination are thought to be part of these 
HMM complexes. Unpublished evidence from collaborators in the D’Aquila Lab at 
Northwestern University Medical School indicate that the A3G His186Arg change causes a 
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visible difference in levels of HMM and LMM complexes of A3G by Western Blot (data not 
shown). It is possible that a shift in the levels of HMM and LMM A3G could cause slight 
differences in the ability to deal with endogenous retroelements, which may alter how the 
adaptive immune system recognizes them. A change in the adaptive immune system could 
theoretically change the balance of different immunoglobulins. In the context of already sick 
children this could theoretically cause further immune dysfunction. 
Despite the lack of an established mechanism to connect A3G and a Deficiency of 
Humoral Immunity, our evaluation of CPT codes shows that individuals are receiving 
intravenous immunoglobulin. Manual review of records for many carriers of the Arg allele 
indicates that many individuals in our dataset who receive ICD-9 codes indicating 
hypogammaglobulinemia or common variable immunodeficiency have additional medical 
problems. Many of the younger children in our dataset who were carriers and cases had notes 
indicating B-cell Acute Lymphoid Leukemia in their records previous to the Deficiency of 
Humoral Immunity ICD.9 codes, often by many years. While there is a well-established link 
between Chronic Lymphoid Leukemia (CLL) and hypogammaglobulinemia,
84–86
 we did not see 
any association with CLL. In fact, when tested, the children who had ALL produced only a small 
signal, and those with both ALL and hypogammaglobulinemia produced a smaller signal than 
hypogammaglobulinemia alone. It is possible that our characterization of both CLL and ALL in 
the PheWAS was extremely poor, and our power to observe an association between His186Arg 
and either of these cancers was reduced or eliminated by poor phenotyping.  
Interestingly, several of the other members of the APOBEC family, specifically 
Activation Induced Deaminase (AID) and APOBEC3B (A3B), have been associated with 
cancers
87,88
. One of the hypothesized reasons that A3G forms the HMM complex in the 
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cytoplasm is to stop it from entering the nucleus at certain times in the cell cycle where it could 
potentially damage single stranded DNA
83
, though evidence shows that A3G is excluded from 
accessing chromatin at all stages of mitosis
89
.  Normally, AID plays a role in hypermutation, 
class switch recombination, and gene conversion; the three processes for secondary antibody 
diversification in activated B-cells
90,91
. Mutations in AID have also been associated with hyper-
IgM syndrome
92
. 
We did not see any signals specifically due to viral infection or any cancers. The only 
Phecode other than Deficiency of Humoral Immunity that even passed the suggestive 
significance line in our analysis was for Hallucinations. In the younger age datasets nothing else 
was even close to the threshold of suggestive significance. Given the multiple associations of this 
gene, and all others in the family, it was unexpected that the SNP was not pleiotropic in our 
analysis.   
Given this association, the previous evidence of the role of His186Arg in HIV, and the 
unpublished data from our collaborator, we decided to search the GTEx
93
 database to see if 
His186Arg was identified as an eQTL. In the relevant tissue, whole blood, rs1877832, the SNP 
responsible for the His186Arg change was an eQTL for A3G (t= -3.3, p=0.001) (Figure 2-G) 
though this was not significant once the total number of tissues tested was adjusted for. This 
effect was consistent across the vast majority of the GTEx tissues, where every copy of the Arg 
allele at A3G 186 decreased the expression of A3G.  
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Figure 2-G. Rank normalized gene expression of APOBEC3G from whole blood for 
homozygous reference, heterozygotes, and homozygous alternate individuals for the His816Arg 
allele.  
 
One of the main limitations of our study is the small number of children available, 
especially given the low minor allele frequency of the His186Arg variant. We attempted to 
explore this variant further in African American children as the variant is far more frequent in 
populations of African descent (~27% MAF), but in the more than 3000 African Americans in 
our dataset, there were only two PheWAS cases for Deficiency of Humoral Immunity. Despite 
this, we feel the association seen in Caucasian children is reasonable. 
            There is limited evidence of the function of A3G in children. Studies exploring the 
deamination ability of A3G in HIV-1 infected children found that the level of A3G did not differ 
statistically based on the level of A3G induced hypermutation
94
. Many studies in both children 
and adults with HIV-1 have found that the Arg genotype of A3G His186Arg is associated with a 
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significant decline in CD4 count
95
. Another study found that the Arg allele is associated with 
more rapid HIV-1 progression and central nervous system impairment in children
96
. While there 
is evidence that the adaptive immune systems of children are different than those of adults
97
, how 
those differences might result in hypogammaglobinemia only in children remains unexplained. 
 In conclusion, we found the A3G His186Arg variant to be associated with a Deficiency 
of Humoral Immunity in a PheWAS and the ICD-9 code for Hypogammaglobulinemia in a 
targeted analysis. More analysis on the function of this variant in contexts outside of HIV-1 
infection are necessary to understand its biological importance and further explore the 
association we saw. Further analysis of this variant in non-European descent populations will 
also be important if this association is generalizable to other racial and ethnic groups. 
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III.  THE ASSOCIATION OF THE APOBEC3B DELETION WITH CARDIAC VALVE 
PHENOTYPES 
 
Introduction 
 
The APOBEC3s (A3) are a family of cytidine deaminases located on chromosome 22 
(Chapter II –Introduction). The deletion of APOBEC3B (A3B) is a germline copy number variant 
that deletes the entirety of the coding region of A3B
98
. This deletion spans 29.5kb from the last 
exon of APOBEC3A (A3A) through the last exon of A3B, thereby removing the whole A3B gene 
and creating a fusion transcript that attaches the protein coding region of A3A to the 3’ UTR of 
A3B
99
 (Figure 3-A-a). This A3A_B fusion transcript is more stable than normal A3A, causing an 
increase in the level of A3A enzyme
99
. This deletion occurs in 6% of individuals of European 
descent, 9% of African Americans, and 37% in Asians
98
.  
 
 
Figure 3-A. Location of the A3B deletion. a) The fusion transcript created spans from the last 
exon of A3A to the 3'UTR of A3B. b) Location of A3A, A3B, and the A3A_B fusion transcript 
in the context of the A3 gene family. 
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Recently, much attention has been devoted to understanding the role of the A3A and A3B 
in cancer. These proteins, part of the larger A3 family (Figure 3-A-b), have been established as 
the most likely cause of “mutation clusters” or “kataegis” seen in a variety of cancer types100–102. 
Both A3A and A3B are found in the nucleus
103,104
, and these two proteins, like other members of 
the A3s cause deamination at cytosines on single-stranded DNA, resulting in C to T 
transitions
72,105,106
. The cytidine deaminase activity of A3B has been found to be a source of 
mutation in breast and other cancers
88
. The deletion of A3B has been found to increase the risk 
of breast cancer in both Asian and European women
107,108
, possibly through the upregulation of 
A3A. In addition to cellular mutation and cancer, members of the A3s are involved in innate 
immunity to retroviral infection
109,110
 and inhibition of endogenous retroelements
111,112
.  
The importance of this deletion has also been investigated in conjunction with infectious 
disease phenotypes. This deletion was found to be associated increased attenuation of the 
Hepatitis B Virus and hepatocellular carcinoma
113–115
, and has been implicated in resistance to 
malaria
116
. The A3B deletion has been tested for an association with HIV, however results have 
been mixed
117,118
. A3A and A3B have also individually been tested for their importance in 
infectious disease phenotypes. As studies in both cancer phenotypes and infectious diseases 
have shown the A3B deletion to be pleiotropic, we hypothesized that it would have 
additional disease associations.  We tested this hypothesis with using a PheWAS in the 
hopes that we could validate existing phenotypes while discovering new ones.  
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Methods 
 
 
BioVU dataset 
In our preliminary analysis, we used individuals for whom DNA had been collected in 
BioVU, Vanderbilt’s de-identified DNA databank. These samples are linked to electronic 
medical records with all identifying information removed. A subset of individuals in BioVU 
have had genotyping performed on one or more of several platforms, the Illumina Omni-Quad, 
the Illumina 660W, and the Illumina Omni5-Quad . For our discovery analysis, we used data 
from 6332 individuals genotyped on the Illumina Omni-Quad, though data for individuals on all 
platforms was obtained. Age at last record was calculated for all individuals based on their date 
of birth and the last ICD.9 code represented in their medical record. Individuals with a third-
party identified race that was not listed as white or an age at last ICD-9 record less than 18 were 
removed leaving 4948 individuals with phenotypic and demographic data.  
 
Genetic Data Quality Control and Deletion Imputation 
Called genotypes underwent QC before imputation. Each platform underwent quality 
control separately. Briefly, SNPs with a genotype efficiency of less than 98% were removed, as 
were individuals in whom fewer than 98% of SNPs were genotyped. Relatedness between 
individuals in the dataset was checked, and related individuals were removed. Sex and 
Mendelian inheritance checks were also performed. Strand alignment and pre-phasing of study 
genotypes was done with Shapeit
119
.The reference panel used for phasing and imputation was the 
1000Genomes Phase 1 version 3. Imputation was performed on each platform separately using 
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Impute2
120
 in chucks of 5MB. Post-imputation genotypes were called based on a 90% threshold 
filter on the Impute2 values. Genotypes for the A3B deletion were extracted.   
 
eMERGE dataset 
Our replication analysis was performed in individuals genotyped as part of eMERGE 
1
121
. These individuals were from one of four sites, Group Health Cooperative, Marshfield 
Clinic, Mayo Clinic, or Northwestern; each site has a DNA biorepository linked to an EMR, and 
individuals at these sites were genotyped on the Illumina 660W 
27
.Individuals from Vanderbilt 
University are also part of eMERGE, but these individuals were excluded from our study group 
to eliminate possible overlap. Genotype QC and imputation was performed as described above 
for the BioVU dataset.  
 
PheWAS and Phecode correlation 
For individuals in each of our datasets, complete ICD-9 code records were obtained, 
along with the date of each ICD.9 code entry. PheWAS case, control, and exclusion status was 
determined using a minimum of two ICD-9 codes in a category to be a case, as described 
previously. PheWAS analyses and meta-analysis were  performed using the PheWAS package in 
R
50
. Bonferroni, false discovery rate (FDR), and Simple-M corrections were used.  Correlations 
amongst PheWAS codes in individuals in our dataset were also determined using pairwise 
Pearson correlation tests. Correlations were plotted using the “correplot” package in R. 
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Ejection Fraction Analysis 
Ejection fraction (EF) data was obtained for a subset of individuals in our dataset. Data had been 
previously extracted by the Denny group. Ejection fraction measures greater than 55 were 
censored to 55 as this was a common cut off for clinical practice. Once patients have an ejection 
fraction of 55, they clearly do not have a reduced ejection fraction, so many physicians will enter 
55 for any number over 55. Summary measures including median, maximum, and minimum 
ejection fraction were calculated. Individuals were also classified dichotomously as having a 
high EF if their median EF was greater than 50. Median EF measures were split into three 
groups, those greater than 50, 35-50, and less than 35. These thresholds were chosen following 
consultation with physicians. Allele frequency for the A3B deletion was compared across these 
groups. A secondary analysis was performed where individuals that were Aortic valve 
malfunction cases from our PheWAS were removed, as we might expect them to have a different 
range of ejection fraction than other patients.  
 
Statistical Analysis 
We performed PheWAS using logistic regression on PheWAS codes with more than 20 
individuals identified as cases. Age at last ICD.9 code in record, gender, and the first three 
principal components were included as covariates in the regression. For the replication in the 
eMerge dataset, site was included as an additional covariate in our logistic regression analysis. 
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Results 
 
The A3B deletion imputed with an information score of 0.76 on the Illumina Omni-Quad 
used in our discovery analysis. From our BioVU population of 5198 white individuals we were 
able to impute an A3B deletion genotype for 4230 of them (Table 3-A). These 4230 individuals 
were our discovery population. 
 
Table 3-A. Summary statistics of individuals genotypes on the Illumina Omni-Quad and used for 
PheWAS after QC measures were implemented. Shown in the whole dataset and by deletion 
status. 
 All 
n=4829 
A3BΔ==0 
n=3471 
A3BΔ==1 
n=443 
A3BΔ==2 
n=16 
Gender M (%M) 2581 (53.4) 1845 (53.2) 246 (55.5) 10 (62.5) 
Median Age last 
record (IQR) 
61 (49, 71) 61 (49, 71) 60 (47, 71) 58 (46, 67) 
  
Phenotype categories were defined through sets of related ICD.9 codes. We required that 
a phenotype have at least 20 cases for analysis, and 908 PheWAS codes met that requirement, 
resulting in a Bonferroni corrected significance threshold of 0.05/908 = 5.5e-05, though this 
correction is overly stringent given that the tests are not truly independent. Three of the 
phenotype categories reached the Bonferroni corrected significance level (Figure 3-B). All of the 
phenotype categories that passed a suggestive significance level of 0.001 were related to 
abnormalities in cardiac function (Appendix I). Heart Failure NOS was the most significant hit 
(OR [95% CI] =2.03 [1.46, 2.82]; p= 2.63E-05), followed closely by Nonrheumatic Aortic Valve 
Disorders (1.98 [1.42, 2.76]; p=5.02E-05). The category for Systolic/diastolic Heart Failure also 
passed our Bonferroni correction threshold (1.65 [1.30, 2.11]; p=5.16E-05). Two more closely 
related phenotypes, Heart Valve Disorders and Heart Failure, also passed the FDR and Simple-M 
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corrections in our data (Table 3-B). All of these had substantial numbers of case individuals, well 
over the minimum 20 required by our analysis.  These phenotype associations with the A3B 
deletion were used for replication in the eMERGE dataset.  
As we saw a large number of cardiac related PheWAS codes appear as significant, we 
considered whether the same individuals might be driving the association of many different 
codes. Correlation tests amongst all Phecodes that reached the level of p=0.01 or better in 
analysis showed that while there is some overlap between all the cardiac codes, not all cardiac 
codes are correlated (Figure 3-C). Heart Failure NOS and Aortic Valve Disorders, our top two 
hits, while made up of different ICD-9 codes (Appendix J), have partially but not completely 
overlapping case populations. 158 out of the 299 individuals with Aortic Valve Disorders were 
also Heart Failure NOS cases (Figure 3-D). This amounted to 16.8% of Heart Failure NOS 
patients.  
 58 
 
Figure 3-B.PheWAS manhattan plot. Groups of PheWAS categories are displayed on the x-axis. 
Red line indicates level of Bonferroni correction (5.45 e-5) and black line indicates line of 
suggestive significance (0.001). All dots above the green line are those that are significant 
according to the FDR and Simple-M phenotypes corrections implemented in PheWAS. 
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Figure 3-C. Pairwise correlations amongst PheWAS codes that had a p-value of less than 0.01 in 
our A3B deletion analysis. Cells marked “?” have no individuals with complete pairwise records.   
 
 
Figure 3-D.Venn diagram of overlap of individuals who are cases for Heart Failure NOS and 
Nonrheumatic Aortic Valve Disorders Phecodes. 
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To attempt to confirm our analysis, we performed a meta-analysis within BioVU. We 
performed PheWAS in the Omni5-Quad (1,599 individuals) and 660W populations (3,532 
individuals) before performing a fixed-effect meta-analysis. The A3B deletion had an imputation 
score of 0.72 on the 660W and 0.9 on the Omni5-Quad. None of our top hits from the Omni-
Quad were significant in the other two datasets (Figure 3-E), though the meta-analysis result was 
trending towards significance. The case distribution was quite different between the three sets, 
with far greater case number and case/control ratio for Heart Failure NOS on the Omni-Quad 
than on the other two platforms. The same was true for Nonrheumatic Aortic Valve Disorders. 
The meta-analysis resembled the Omni-Quad results far more than the other platforms, possibly 
due to the uneven case distribution.  
In the eMERGE dataset, we only evaluated those categories that were significant in our 
preliminary analysis. The eMerge dataset consisted of 14,104 European American individuals 
from four different medical centers. The three heart failure codes (Heart Failure NOS, 
Systolic/diastolic Heart Failure, and Heart Failure) that were significant in our Omni-Quad 
discovery analysis were not significant within the eMERGE set. We only evaluated specific 
Phecodes seen in our discovery analysis in the eMerge set; we did not test other codes outside 
those targeted for replication. Both Nonrheumatic Aortic Valve Disorders (1.29 [1.00, 1.66], 
p=0.046), and Heart Valve Disorders (1.26 [1.05, 1.51], p=0.01), were significant at the p=0.05 
level in our replication (Table 3-C). We attempted to replicate five codes, only Heart Valve 
Disorders was significant at the level of the Bonferroni correction.  
In our data, the presence of the A3B deletion was not associated with a lower minimum 
ejection fraction in all individuals, but once individuals with the Nonrheumatic Aortic Valve
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Figure 3-E. Forest plot of PheWAS results for Heart Failure NOS and Nonrheumatic Aortic Valve disorders codes in all BioVU sets 
and in a fixed effects meta-analysis. 
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Table 3-B.Results from the PheWAS that pass the FDR and simple-M correction thresholds. 
PheWAS Code PheWAS Code Description OR (95% CI) p-value N cases N controls 
428.2 
Heart Failure NOS 
2.03 (1.46, 2.82) 2.63E-05 260 2389 
395.2 
Nonrheumatic Aortic Valve Disorders 
1.98 (1.42, 2.76) 5.02E-05 244 2887 
428.1 
Systolic/diastolic heart Failure 
1.65 (1.30, 2.11) 5.16E-05 772 2389 
395 
Heart Valve Disorders 
1.61 (1.26, 2.05) 0.00016 586 2887 
428 
Heart Failure 
1.56 (1.24, 1.98) 0.00019 865 2389 
 
Table 3-C. Replication of hits from preliminary PheWAS in the eMERGE dataset. 
 
PheWAS Code PheWAS Code Description OR (95% CI) p-value N cases N controls 
428.2 Heart Failure NOS 1.04 (0.68, 1.66) 0.78 271 8776 
395.2 Nonrheumatic Aortic Valve Disorders 1.29 (1.00, 1.66) 0.046 898 10164 
428.1 Systolic/diastolic heart Failure 1.05 (0.85, 1.29) 0.66 1994 8776 
395 Heart Valve Disorders 1.26 (1.05, 1.51) 0.01 586 10164 
428 Heart Failure 1.08 (0.88, 1.32) 0.46 865 8776 
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Disorders Phecode were removed, the we saw that the deletion was associated with lower 
minimum ejection fraction  (B [95% CI] = -4.40 [-8.03, -0.77)]; p=0.02) (Table 3-D). Since the 
deletion was associated with valve disorders in our analysis, we were concerned that these 
individuals might have low ejection fraction levels and bias our analysis. As it is often not the 
exact measure, but whether individuals are below a certain threshold, that is clinically important, 
we also tested the impact of the variant on whether individuals had a low ejection fraction. In the 
whole population, the variant was not quite significant (OR [95% CI]=1.44 [0.98, 2.13], p=0.06), 
while in the group lacking the aortic valve malfunction, a copy of the deletion increased the odds 
of having a median ejection fraction considered low (2.26 [1.17, 4.36], p=0.02) (Table 3-E). 
 
 
Table 3-D. Association of the A3B deletion with minimum ejection fraction in all individuals 
and all individuals except those that were Nonrheumatic Aortic Valve Disorders cases in our 
PheWAS. 
 
All 
(n=1,051) 
All except Aortic Valve Malfunction 
(n=482) 
 Minimum Ejection Fraction Minimum Ejection Fraction 
A3BΔ Allele -1.71 (-4.12, 0.70) p=0.17 -4.40 (-8.03,-0.77) p=0.02 
Age at Minimum 0.05 (-0.01, 0.10) p=0.09 0.005 (-0.07, 0.08) p=0.89 
Sex==M -4.48 (-6.20, -2.76) p=4.1e-07 -4.53 (-6.90, -2.15) p=2.1e-04 
 
Table 3-E. The role of the A3B deletion in increasing the odds of having a median ejection 
fraction classified as low. 
 
All 
(n=1,051) 
All except Aortic Valve Malfunction 
(n=482) 
 Low Ejection Fraction Low Ejection fraction 
A3BΔ Allele 1.44 (0.98, 2.13) p=0.06 2.26 (1.17, 4.36) p=0.02 
Age at Minimum 0.99 (0.98, 1.00) p=0.22 1.00 (0.99, 1.02) p=0.71 
Sex==M 2.03 (1.49, 2.78) p=9.2e-06 2.77 (1.57, 4.90) p=4.6e-04 
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 As breast cancer has been previously associated with the A3B deletion
88,107
, we checked 
for an association in our population. The phenotype category Breast Cancer had 162 cases with a 
nonsignificant OR = 1.1 [0.72-1.83], p=0.56. Because the controls in our general analysis were 
both men and women, we performed a specific analysis using only females. In the female-only 
analysis the code for breast cancer was still not significant (OR = 1.2 [0.75-1.93], p=0.44), so we 
did not replicate the previously reported association
88,107
. Furthermore, no infectious disease 
phenotypes reached either significant or suggestive p-value levels, despite the known role of the 
A3 proteins in viral infection control
109,114,122
. The infectious diseases previously associated with 
the A3B deletion, HIV
117
 and HBV
115
, were tested in our PheWAS but had very few cases each 
(36 and 25 respectively).  
 
Discussion 
 
The association of the A3B deletion with phenotypes relating to heart function was 
unexpected. Previous associations have been to viral phenotypes and cancer risks and changes in 
the characteristics of enzymatic mutation in cancer
88,99,102,107,114,115
. One possible hypothesis for 
why the A3B deletion could be associated with heart phenotypes is that in heart tissue the 
deletion causes inflammation, which results in valve issues. However, endocarditis was not 
significantly associated with the A3B deletion in our discovery dataset (OR = 1.4 [0.74, 2.62], p 
= 0.30, 69 cases). If an inflammation related mechanism was at the base of this association, it is 
possible we would not see if despite testing for PheWAS codes including endocarditis because 
not all individuals who have effects from this process are severe enough to be diagnosed as such 
or the ICD.9 code for endocarditis is a poor marker for the actual phenotype. It is also possible 
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that a subset of individuals in this dataset have an infection to which the A3s would respond 
which is driving an association though it is not captured well by ICD.9 codes or we only capture 
it through secondary manifestations. Despite this, we were able to replicate the associations of 
valve phenotypes in an independent EMR dataset. 
As we saw so many cardiac phenotypes in our dataset, it is not clear if the true 
association is to a phenotype represented by the Phecodes we saw or to some other condition for 
which people may be billed with one or more of these ICD-9 codes prior to or during diagnosis. 
There are clearly two distinct populations of cardiac phenotype patients that are enriched for the 
A3B deletion in the Illumina Omni Quad set in BioVU, though only one of those populations 
replicated. These populations seem to be quite different than those on the other BioVU 
genotyping platforms and those in eMerge. As each GWAS platform in BioVU was put together 
based on the presence and absence of individuals with specific phenotypes, it is not surprising 
that the results may be different across platforms. For example, the 660W was assembled 
partially to reduce the presence of cardiac patients on the platform; a vital distinction for our 
analysis. As all controls for PheWAS are potentially case patients for other phenotypes, it is 
possible that this ascertainment procedure causes some difference in association between the 
platforms. In the eMerge set we had to account for the different sites which contributed data, 
especially since each site’s population is ascertained with different criteria.  
The major limitation of this study is that we were unable to replicate previously known 
associations. Our inability to replicate associations with HIV is perhaps not surprising as well 
phenotyped cohorts have discordant results on whether that association is real
123–125
. 
Susceptibility to HBV is another previously existing association of the A3B deletion that we 
were not able to replicate, but case numbers were low, and the availability of a vaccine was not 
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accounted for within the PheWAS controls.  For both of these diseases it is likely that PheWAS 
aggregations of ICD-9 codes alone provide inadequate information for ascertainment of true 
cases and controls.  More concerning is that despite the known association of the A3B deletion 
with multiple cancers, we did not see a signal for any cancers in our analysis. One possible 
reason for this is that the aggregation approach used in PheWAS may not be ideal for capturing 
cancers. While some cancers may be ascertained well if one instance of an ICD-9 code is 
present, others may require 3 or even four instances of ICD-9 codes before they are well 
captured. By requiring two ICD-9 codes for case status, we would be excluding many true cases 
in the former scenario, and falsely classifying individuals as cases in the latter. Both these 
options would cause us to lose power through poor phenotype ascertainment. Also, some of the 
cancers the A3B deletion has been associated with predominantly or only occur in a single sex. 
As our initial PheWAS was mixed sex, we would have decreased our power to see these cancers. 
Despite this, we had assumed we would be able to see a cancer signal before we began our 
analysis. 
Another potential limitation of the study is the genotype itself. The A3B deletion was 
imputed, and while we understand that deletions with reasonable imputation scores should be 
robust (unpublished communication with Evan Eichler), it does leave a certain amount of 
uncertainty in our data. Furthermore, deletions genotypes were assigned absolutely instead of 
using the probability of being a certain genotype for analysis. This means that we have far more 
individuals with missing genotypes than theoretically possible. It also means that more 
individuals are missing the genotype than are missing the SNPs used to impute it, resulting in a 
lower minor allele frequency than many reference populations and other studies report. While the 
imputed genotype does add a degree of uncertainty, there is only one SNP in A3B in strong LD 
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with the deletion, and it is not commonly placed on GWAS platforms. Using the imputed 
deletion allowed us to test a genetic variant that would not have otherwise been possible. This 
assignment of genotypes also creates an issue when analyzing multiple genotyping platforms 
together. Different platforms impute the A3B deletion with different imputation scores, and this 
affects the number of people confidently assigned a genotype. In BioVU, proportionally far more 
individuals on the 660W were missing genotypes than for the Omni5-Quad, because the SNP 
imputed with much greater confidence on the Omni5-Quad.  
Despite these limitations, we were able to find and replicate a novel association of the 
A3B deletion with Aortic Valve phenotypes and provide substantial evidence that the A3B 
deletion is important in a number of cardiac related conditions. Future studies in carefully 
phenotyped cohorts will be important for identifying the condition underlying these PheWAS 
associations.    
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IV.  CHARACTERIZATION OF COMMON DELETIONS ACROSS THE GENOME BY 
THEIR PHENOTYPIC IMPACT 
 
Introduction 
 
 
While SNPs are the most frequently analyzed genetic variants in the genome, they are far 
from the only variation present in the human genome. Deletions large enough to be classified as 
structural variants (SVs) or copy number variants (CNV) are present throughout the genome. 
These CNVs may be individually rare, but many occur in the population
126
. Deletions have long 
been associated with rare diseases
127,128
, and more recently have been investigated for their 
impact in common disease
129
.  
While structural variants have traditionally been difficult to detect, the 1000 Genomes 
database provides a detailed view of both single nucleotide and large polymorphisms in humans 
The phase 1 version 3 research identified more than 14000 large deletions
130
. 1000 Genomes 
defines a SV as an insertion or deletion of 50 basepairs (bp) or larger. Despite a growing ability 
to examine the importance of these deletions in previously obtained data, their impact in disease 
is still not clear. Previous publications on genome-wide CNVs have concluded that common 
CNVs will not account for much of the unexplained heritability in diseases
131
, and some have 
even tested all common CNVs in the genome with a limited group of phenotypes, and have 
found few or no associations
129
. Despite this, smaller studies have found that deletions may play 
an important role in some diseases including schizophrenia
132
, autism spectrum disorders
133
, 
autoimmune diseases, HIV
134
, and risk for certain cancers
108
. CNVs have also been shown to be 
responsible for a portion of the differences in gene expression between individuals
135
.  
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Deletions provide us with a “natural knock out” experiment, allowing us the clearest 
picture of what happens in a human when a piece of DNA is removed. Understanding the impact 
of removing areas of genes, areas of non-coding DNA that are regulatory elements, or areas that 
don’t appear to be either, will enhance our understanding of how our genome contributes to 
disease. We can also examine the impact of the amount of the genome deleted, which will give 
us insight as to whether the size or position of the feature is generally more important. We 
hypothesized that different deletions would have different likelihoods of causing a 
phenotypic consequence depending on deletion characteristics like size and location. For 
example, a deletion overlapping all or part of an exonic region of a gene would be more 
likely to result in a phenotypic effect than those that that did not. We tested this hypothesis 
by performing PheWAS on imputable deletions in BioVU. 
 
Methods 
Deletion Calling 
Initial data processing involved quality control of both the genotype data, and phenotype 
processing. Genotyping performed on the Illumina Omni-Quad GWAS chip was available for 
5,198 self-identified white individuals in BioVU. SNP quality control and imputation is 
described in Chapter 3. While SVs have long been identified as potentially problematic for 
imputation
136,137
, newer reference panels including 1000 Genomes allow imputation with 
reasonable accuracy (unpublished communication with Evan Eichler). A total of 13,805 
deletions were imputed using 1000 Genomes Phase 1 version 3 as a reference panel. These 
deletions were put through a pipeline to prepare them for analysis (Figure 4-A).  
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Figure 4-A. Flowchart of deletion imputation, PheWAS code aggregation, and data merging. 
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Deletion Mapping and Categorization 
First we mapped each imputed deletion to the list of structural variants available through 
the database of genomic variants (DGV) 
138
 using tabix. For this project we used the “esv” 
annotation, which denotes structural variants that were submitted by the European 
Bioinformatics Institute (EBI). Any deletion that did not map to an esv or mapped to more than 
one esv was removed. Next we removed any deletions that did not have a minor allele frequency 
(MAF) of at least 5% or an imputation score of > 0.7 in our population. This left us with 1,255 
deletions for analysis. LD was tested in these deletions and deletions with an r2 >=0.5 were 
identified. We were left with 1167 unique deletions.  
BED files for structural variants were assembled using start and endpoints as determined 
from dbVar
139
 dataset estd199, the structural variants submitted for 1,092 individuals sequenced 
by the 1000 Genomes Project 
(http://www.ncbi.nlm.nih.gov/dbvar/studies/estd199/#experdetailstab). The extent to which 
imputed deletions overlapped with genes (start and end positions) or individual exons was 
determined using BedTools
140
 specifically the intersectBed function. Bed files containing all 
RefSeq transcripts
141
 were downloaded from the UCSC Genome Browser (hg19, refflat table)
142
. 
In order to include each gene just once, we selected transcripts with the earliest transcriptional 
start point and the most distant transcriptional endpoint. In addition, BED files were created for 
the exon of each gene including all exons across multiple isoforms with one or more transcripts 
but with each exon represented only once. The dataset includes over 14 thousand larger deletions 
and captures 98% of variants at 1% frequency enabling the imputation of both common and low 
frequency structural variants. While the majority of variants had clearly defined start and 
endpoints, for several the exact base pair at which the structural variant begins could not be 
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determined with absolute certainty. In these cases, we used the widest region defined by the 
confidence interval, termed “outer-start” and “outer end” in this dataset. 
 
Population Demographics and Phenotypic Data 
Demographic data and ICD-9 code records were obtained. ICD-9 codes were aggregated 
into PheWAS codes as described previously and displayed in Figure 4-A. Sex was obtained from 
third party reporting, and age at last ICD-9 code entry was calculated from date of birth and the 
ICD-9 code record. Data was stratified to only include individuals of European descent with an 
age at last record over 18.  
 
Statistical Analysis 
 PheWAS were performed as logistic regression adjusting for age at last record, sex, and 
the first three principal components using the PheWAS package in R. Statistics for the deletion 
predictor from PheWAS outputs were compared using Kolmogorov–Smirnov (ks) tests and 
Wilcoxon rank sum tests. Statistical analyses were performed with R
51
.  
 
Results 
 
We imputed 1310 deletions. These deletions had info scores between 0.7 and 1, with 1 
being the most common (Figure 4-B-a). 283 deletions had a minor allele frequency between 5% 
and 10%, and the number of deletions in each 5% bin decreased until 40% (Figure 4-B-b).   The 
majority of these deletions did not overlap a gene, and only 9 overlapped more than 2 genes 
(Figure 4-B-c).
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Figure 4-B. Characteristics of imputed deletions. Distribution of a) imputation info scores, b) minor allele frequencies, and c) number 
of genes overlapped.
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Our population consisted of 5198 individuals of European descent previously described 
in Chapter 3(Table 3-A). These individuals had a median age at last code of 61 years old. While 
most of these individuals were PheWAS cases for between 20 and 30 PheWAS codes, some 
were PheWAS cases for over 200 codes (Figure 4-C-a). Individuals had an average of just under 
60 deletions, and around 25 deletions that overlapped genes (Figure 4-C-b).  
 
Figure 4-C. Distribution of a) PheWAS codes and b) deletions in individuals in the set. 
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We then compared deletions that overlapped genes with those that did not. While QQ 
plots show that p-values in deletions overlapping a gene did not substantially deviate from what 
was expected (Figure 4-D-a), and overall did not result in impressive p-values (Appendix K). By 
comparison, those that were not annotated as overlapping a gene visually appeared to have more 
significant p-values than what was expected (Figure 4-D-b). A ks test could not statistically 
determine that these two groups of p-values were drawn from different distributions (p=0.076) 
despite being visually distinct on QQ plots. QQ plots provide a mediocre comparison as we 
notice the inflation of a few specific points many of which are from a single deletion (Appendix 
L), while the lower left corner of the plot has far for data points in it. As deletions were assigned 
as overlapping a gene based on coordinates alone, we wanted to see if overlapping an exon made 
a difference in the best p-value resulting from testing each deletion with PheWAS. There was no 
significant difference (p=0.26) in the distribution of the best p-value of deletions overlapping an 
exon (Figure 4-D-c) and those annotated as overlapping a gene but not an exon (Figure 4-D-d). 
We also wanted to explore if the length of the deletion was correlated with the most significant 
p-value in PheWAS, but there was no correlation (p= 0.69). 
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Figure 4-D. QQ Plots of deletions with different characteristics; a) deletions overlapping a gene, 
b)deletions not overlapping a gene, c) deletions overlapping a gene and an exon, d) deletions 
overlapping a gene but not an exon. 
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Discussion 
 
Overall, we found that we could not successfully characterize deletions using PheWAS. 
The statistical significance of PheWAS hits did not seem to be different by whether a deletion 
overlapped a gene, exon or neither a gene nor an exon. If anything, deletions not annotated as 
overlapping a gene were the most significant in our analysis. Given that the majority of 
significant GWAS SNPs are in intergenic regions, this is not necessarily surprising. It is perhaps 
more surprising that deletions removing more of the genome are not more likely to give a 
phenotypic association with a lower p-value. One would assume that these deletions would be 
more likely to overlap something functional, whether coding or not. These analyses may have 
been limited by the correlation present in the phenotypic data of the PheWAS, and are certainly 
limited by the deletions we could reliably impute. 
The length of deletions and its potential overlap has been determined by the outermost 
endpoints of the deletion and the gene. For many of the deletions there was one consensus start 
position and one consensus end position, but a small subset of the deletions had an “inner” and 
an “outer” start and end position listed. For these deletions with uncertain length we used the 
“outer” positions for both the start and the end. This may have artificially inflated the length of 
some of the deletions. It is unclear whether this had an impact on the PheWAS associations. For 
some deletions, the “outer” endpoint may have overlapped a gene where the “inner” endpoint 
would not have. To further complicate this, there may be other listed coordinates than the “outer” 
and “inner” that fall between the two, all of which may actually exist in individuals.  
When we annotated a deletion as overlapping a gene, we did not mean that it had to touch 
the exonic region. As many as a single base pair of the deletion coordinates could overlap with 
the gene coordinates, and we would have counted it as overlapping. This is problematic, as a 
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deletion that overlaps five base pairs of a region annotated as a gene would be expected to have a 
different impact than a deletion that removes the entirety of a gene including all its exons. The 
exon overlap criteria helped with this, but some deletions were located in introns and could 
change the splicing of a gene making our reference coordinates inappropriate for the gene as it 
occurs. All these issues with overlap may have caused us to incorrectly classify deletions, 
reducing our ability to see an association.  
RefSeq includes as “genes” many long non-coding RNAs and other transcripts with 
unknown function. One solution would be to limit our analysis to only protein coding genes. We 
could do this by using a second database such as Ensemb, to annotate protein-coding genes, and 
only use entries that are shared between the two databases. This may still leave us with some 
transcripts and RNAs, but at least we will know all "genes" are in standard locations.  A third 
option is to manually curate the genes we use. Some of the entries are named as anti-sense 
transcripts or lnc RNAs. These should not have any entries in the RefSeq exon list, and we 
should be able to remove them. We could then re-annotate our deletions to ensure we are only 
including deletions that overlap protein coding genes.  
Another potential issue is that we are using imputed deletions. While deletion imputation 
should be statistically the same as imputing SNPs, imputation of deletions is not widely 
published. A separate project in which we are participating is beginning to compare imputed and 
directly genotyped deletions to determine concordance. Additionally, calling the deletions from 
intensity data in the genotyping platforms may be a more appropriate way to capture them. Even 
deletions called from intensity data will be subject to a major limitation that is important for our 
study, we are limited by the SNPs on the genotyping platform. In this case, the distribution of 
SNPs will affect the deletions we capture as is the tagging nature of the GWAS platform. It is 
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quite possible that if we have ascertained all deletions throughout the human genome, our results 
would like quite different.  
In conclusion, PheWAS does not seem an ideal way to classify imputed deletions in this 
study. This is not due to the nature of a deletion compared to other genetic variants; rather the 
difficulty arose from our use of PheWAS as a blanket classification scheme without considering 
how noise in both the genotypic and phenotypic data might complicate our efforts. Correlations 
in the PheWAS phenotypes complicated our ability to analyze results, as did the uneven 
distribution of our deletions across the genome and the different imputation quality present in 
different deletions. Perhaps given a completely random selection of deletions from all across the 
genome all called with the same error we would have been more successful.  Despite the 
difficulties in this project, it is clear that analyzing a deletion instead of a SNP offers a far clearer 
biological hypothesis in the event of an association.  
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V.  MITOCHONDRIAL HAPLOGROUP BACKGROUNDS MODIFY THE PHENOTYPIC 
IMPACT OF SNPS IN GENES RELEVANT TO MITOCHONDRIAL FUNCTION 
 
Introduction 
 
Mitochondria are double membrane bound organelles derived from an -proteobacterial 
ancestor
143
. Mitochondria are dynamic, and one mitochondrion can split into two or multiple 
may merge into one, forming networks throughout the cell
144
.  The outer membrane holds 
proteins necessary for intracellular signaling. The mitochondrial signaling pathways are involved 
in functions as diverse as regulation of metabolism and apoptosis. The inner mitochondrial 
membrane has folds called cristae that increase the surface area on which it can house the 
proteins in the electron transport chain. The electron transport chain facilitates oxidative 
phosphorylation to produce ATP in the cell
145
. Mitochondria have their own genome, but are still 
dependent on more than 1,000 genes encoded in the nucleus for proper function. Nuclear genes 
encode for proteins including Pol, the mitochondrial polymerase, MAVS, the mitochondrial 
anti-viral signaling protein, and BCL2 which is important for apoptosis. In addition to many 
genes involved in mitochondrial signaling and immune response, nuclear encoded genes 
important for cytoskeletal formation and solute transport are essential for mitochondrial health. 
Polypeptides designated for the mitochondrial matrix have an N-terminal localization signal that 
directs them to pass through both membranes and into the mitochondria
146
. 
The mitochondria and its genome are maternally inherited
147
. The mitochondrial genome 
is comprised of a single circular chromosome. The majority of the mitochondrial DNA (mtDNA) 
is double stranded, except for a 1124 bp portion called the D-loop which is triple stranded and 
contains promoter and replication elements
148
. mtDNA encodes 37 genes; 13 proteins important 
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for oxidative phosphorylation, 22 tRNAs, and 2 rRNAs. Multiple copies of the genome can be 
found in each mitochondria, so a cell can contain many copies of the mitochondrial genome
144
. 
As mitochondria are haploid, mutations can accumulate at a much faster rate than they do in the 
nuclear genome
149
. Both mutations and population level variation are present in the 
mitochondrial genome (Figure 5-A). 
 
 
Figure 5-A. Map of the mitochondrial genome with genes and pathogenic mutations annotated. 
Figure was created by www.mitomap.org and is used under the creative commons license. 
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Population level variation in the mitochondrial genome can be phylogenetically grouped 
into haplogroups
150
 (Figure 5-B). Mitochondrial haplogroups can be determined using SNPs 
commonly available on genotyping platforms. Different mt haplogroups function 
differently
151,152
. Haplogroups have been associated with numerous human diseases: haplogroup 
J  has been associated with both susceptibility
153
 to and protection
154,155
 from Parkinson’s 
Disease as well as susceptibility to Multiple Sclerosis
156,157
, and haplogroup H has been 
associated with age related maculopathy
158
.  
 
 
 
Figure 5-B. Mitochondrial Haplogroup tree showing relationship between mitochondrial 
haplogroups. European ancestry haplogroups include I, W, X, J, T, H, and Uk (from U and K 
combined). 
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Genetic variation in both the nucleus and mitochondria are responsible for mitochondrial health, 
but little is known about the relationship of the genetics in the two genomes and their collective 
impact on human disease. As mitochondrial diseases have a variety of phenotypes, we decided 
that a PheWAS would give us the opportunity to detect any possible outcome of nuclear and 
mitochondrial genetic variation. We hypothesized that the phenotypic effect of nuclear SNPs 
relevant to mitochondrial function will be influenced by mitochondrial genetic variation.  
 
Methods 
 
Genotypes and Haplogroup Determination 
Nuclear and mtSNPs were obtained for individuals genotyped on the Human Exome 
Bead chip in BioVU. Heterozygous mtSNPs (due to either genotyping errors or potentially 
heteroplasmy) were set to missing for this analysis. Remaining mtDNA genotypes were 
classified into standard haplogroups using Haplogrep
159,160
.  Fine level haplogroups were then 
assembled into analysis groups using racial information, since mitochondrial haplogroups are 
closely tied to continental ancestry. Individuals not of European descent by provider assigned 
race were removed from analysis.  
Nuclear SNP genotypes underwent quality control. Briefly, SNPs with less than 95% 
genotyping efficiency were removed as were individuals with more than 5% missingness in the 
exome data. All nuclear SNPs with a minor allele frequency (MAF) over 10% present in genes 
on the MitoCarta2 Gene list
161
, a list of genes involved in mitochondrial function, were 
extracted. The high MAF threshold was used since we would be further subdividing the analysis 
by mitochondrial haplogroups with population frequencies of ~10-50%. SNPs were additively 
encoded. 
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Figure 5-C. Flowchart of nuclear and mt SNP filtering and PheWAS performed on SNPs, haplogroups, and for SNP Haplogoup 
modification tests. 
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SNP-Haplogroup Regression Models 
As limited studies have explored the relationship between nuclear and mitochondrial 
SNPs it is not clear exactly how to model the interaction or co-occurrence of the two. We 
decided to model the nuclear-mitochondrial SNP interaction in three ways (Figure 5-C). Model 
1is based on the model traditionally used for SNP-SNP interactions. We will refer to this model 
as the “Main effects model” as it accounts for the main effects of the SNP and haplogroup in 
addition to the SNP-haplogroup effect, which is what we report here in our statistics. Model 2 
models the nuclear-mito relationship without the individual effects of either the SNP or the 
haplogroup. We will call this the “mitochondrial haplogroup mediated SNP effect” model or 
“mtDNA mediated effect” model for short as we are testing individuals with both the SNP and 
haplogroup against those without either the SNP or the haplogroup. Model 3 stratifies by 
haplogroup and determines the effect of the SNP within each haplogroup. We will refer to this 
model as the “stratified model”. All three models were run for all SNP-haplogroup combinations. 
To complement our models and allow us to look at all facets of the data, SNPs and haplogroups 
were each tested alone as well. Regression models were compared visually with QQplots and 
forest plots.  
 
PheWAS 
ICD-9 codes were obtained for all individuals. Duplicate entries, entries with corrupted 
dates, and non-numeric entries were removed. ICD-9 codes were aggregated to PheWAS codes. 
Demographics including sex, date of birth, and third-party assigned race, were obtained for all 
individuals in our set. Age at last ICD-9 code was calculated using the combined date of birth 
and ICD-9 information. Individuals with an age-at-last-ICD-9 code less than 18 or greater than 
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90 were removed. PheWAS was performed using each of the regression models and each variant 
from genes in the MitoCarta2 list, testing all phenotypes with more than 50 cases.  
 
Result Filtering and Prioritization 
PheWAS results were filtered in three major ways. First, we prioritized evaluation of two 
haplogroups, haplogroup H and  haplogroup J. Haplogroup H is the most frequent of the 
European haplogroups (45% of the European descent population) and therefore would likely 
provide the best statistical power. Haplogroup J has the most existing disease associations, which 
provides us a base for which associations are biologically reasonable. The second filter, was 
statistical, and based on p-value, effect size, and the number of cases with the SNP-haplogroup 
combination. We predominantly viewed the results for each haplogroup separately, though we 
did compare the levels of significance of the top hits in different groups. Our last filter was an a 
priori prioritization of the disease categories in PheWAS. We thought that Phecodes in the 
Sensorineural, Neurological, and Musculoskeletal categories were most likely to be true 
associations if the Phecode reached the level of significance. While other disease categories were 
plausible, these would take priority if all else was the same.  
 
Results 
 
The population used to study the relationship between nuclear and mitochondrial genetics 
consisted of 20,064 adults of European descent. Haplogroups H, J, T, Uk, and haplogroup clade 
IWX were common enough to be evaluated; all other individuals were grouped into the category 
of Other. The haplogroup frequencies in our population were consistent with expected 
frequencies (Table 5-A). The median age at last code in our record was 65, and this metric was  
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Table 5-A. Demographic information for individuals of European descent used for our nuclear encoded mitochondria relevant SNP 
haplogroup analysis. 
 All H IWX J 
T 
 
Uk Other 
N (%) 20064 9419 (46.9) 1290 (6.4) 2100 (10.5) 2241 (11.2) 4548 (22.7) 466 (2.3) 
N males (%) 9325 (45.5) 4325 (45.9) 586 (45.4) 981 (46.7) 1068 (47.7) 2157 (47.4) 208 (44.6) 
Median age first ICD.9 
code (IQR) 
56 
(43, 67) 
56 
(43, 67) 
56 
(42, 67) 
56 
(44, 67) 
55 
(42, 67) 
56                
(43, 67) 
54 (40, 67) 
Median age at last code 
ICD.9 (IQR) 
65 
(53, 77) 
65 
(53, 77) 
65 
(54, 77) 
65 
(54, 77) 
65 
(53, 77) 
65 
(53, 77) 
63 (51, 76) 
Median number of 
PheWAS codes (IQR) 
24 
(11, 43) 
24 
(11, 42) 
24 
(11, 45) 
24 
(12, 44) 
23 
(11, 43) 
23 
(11, 43) 
23        
(11,41)      
Median number of ICD.9 
code entries (IQR) 
143 
(68, 280) 
143 
(68, 279) 
146 
(69, 283) 
147 
(69, 282) 
143 
(68, 273) 
141 
(66, 282) 
137          
(70, 265) 
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consistent in all haplogroup subsets. The median number of PheWAS codes that individuals were 
cases for and the number of ICD.9 code entries were also consistent between haplogroups.  
The PheWAS performed in mitochondrial haplogroup alone as a predictor (Figure 5-D-a) 
was much weaker than the signal we saw from SNPs in mitochondrial related genes (Figure 5-D-
b). The PheWAS on the SNPs alone allowed us to see some known signals, including the 
association of SNPs in ARMS2 with age-related macular degeneration (OR [95% CI] ==3.06 
[2.30, 4.07]; p=1.26E-14). The best signal in the haplogroup specific analysis was the Phecode 
for Intestinal Infection Due to C. difficile with haplogroup IWX (OR [95% CI] =2.00 [1.42, 
2.81]; p= 6.4E-05). This was not quite below the Bonferroni correction for Haplogroup IWX 
(p=4.35E-5), and well below the correction when considering all haplogroups.  
From our analysis of SNP- haplogroup co-occurence, one of the most consistent results 
was haplogroup J modifying the effect of rs3736032 in SLC25A37 on Other cerebral 
degenerations, which was the best signal seen in haplogroup J (Appendix M). This association 
was visible using all three of our models (Figure 5-E), though it was by far the strongest using 
the mtDNA mediated effect model (OR [95% CI]= 4.96[3.10, 7.92]., p=2.-3e-11 We saw a 
moderate effect of haplogroup J alone on the Phecode for Other Cerebral Degenerations (1.81 
[1.32, 2.47], p=2e-04), but no signal from the SNP alone (1.27 [0.95, 1.70], p=0.12). In the main 
effects model, Other Cerebral Degenerations was still the best signal we saw (4.38[2.25, 8.55]; 
p=1.48e-05). In our stratified model, the Other Cerebral Degenerations signal was significant in 
haplogroup J (4.00[2.28, 7.01], p=1.28e-06), but not in the not-J group or individually in any of 
the other haplogroups (Figure 5-F). None of the other haplogroups had any significant signal at 
all. Other Phecodes with signals beyond suggestive significance thresholds for J and rs3736032 
were also related to central nervous system complications. 
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Figure 5-D.  QQ plots of p-values from a) PheWAS using mitochondrial haplogroups as predictors and b) SNPs in mitochondria 
relevant genes as predictors. All individuals, males, and females are shown. 
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Figure 5-E.  PheWAS Manhattan plots for the association of rs3736032 on Other Cerebral Degenerations modified by haplogroup J in  
a) the main effects model, b) the mtDNA mediated effect model, and the stratified model c) in haplogroup J individuals and d) in not J 
individuals.
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Figure 5-F. Forest plot of one of the most consistent results, haplogroup J modifying the effect of 
rs3736032 and haplogroup J on Other cerebral degenerations. Effects of SNP, haplogroup, and 
all three models are shown. The association of rs3736032 with Other cerebral degenerations is 
also shown in each non-J haplogroup for completeness. 
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A more unexpected association with a different pattern of expression was the association 
of rs17850652 with Tobacco Use Disorder modified by haplogroup H. This was not the most 
significant hit in SNPs tested for modification with group H (Appendix N), but was an 
interesting phenotype and was fairly consistent across models. While the mtDNA mediated 
effect model was still the most significant of the models tested (1.53[1.29, 1.83], p=1.12e-06) 
(Figure 5-G), the stratified analysis (1.54[1.29, 1.86], p=3.21e-06) looked more like the mtDNA 
mediated effect model, rather than the main effects model (1.68 [1.28, 2.21], p=1.7e-04). In this 
case, the SNP has a small effect alone (1.19 [1.04, 1.36], p=0.01), while the haplogroup alone is 
not significant (1.07 [0.96, 1.19], p=0.22). Despite the difference in p-values, all three models 
provided similar odds ratio estimates (Figure 5-H). No other Phecodes were significant in the 
analysis of this SNP-haplogroup combination.   
As the examples we specifically investigated showed similar odds ratios despite different 
p-values, we wanted to know if this extended to all results. For all SNP-haplogroup-phenotype 
combinations present in both models with a p-value for the interaction term less than 0.01, we 
plotted the betas from the main effects model against those from the mtDNA mediated effect 
model. We found that the betas from the main effects models and the mtDNA mediated effect 
model were highly correlated (p<2e-16) (Figure 5-I). While the p-values from the mtDNA 
mediated effect model tended to be stronger, the betas from the main effects model are slightly 
stronger. The same trend also holds true even when no p-value threshold is placed on the SNP-
haplogroup interaction term.   
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Figure 5-G. PheWAS Manhattans for the association of rs17850652 on Tobacco Use Disorder modified by haplogroup H in  a) the 
main effects model, b) the mtDNA mediated effect model, and the stratified model c) in haplogroup H individuals and d) in not H 
individuals. 
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Figure 5-H. Forest plot of haplogroup H modifying the effect of rs17850652 on Tobacco Use 
Disorders. Effects of SNP, haplogroup, and all three models are shown. The association of 
rs17850652 on Tobacco Use Disorders in other European haplogroups is also shown. 
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Figure 5-I. Correlation of betas from Main Effects model and mtDNA Mediated Effect model. 
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Discussion 
 
We were able to see mitochondrial haplogroup background influence the effect of SNPs 
resulting in phenotypes relevant to mitochondrial function. The modification of association we 
are most confident about is the influence of rs3736032 on Other Cerebral Degenerations in 
haplogroup J. Haplogroup J has previously been associated with Parkinson’s Disease and 
Multiple Sclerosis
154,156
, so the cerebral degeneration related phenotype is reasonable. rs3736032 
causes a Arg96Gln amino acid change in SLC25A37, which encodes an iron transporter on the 
inner mitochondrial membrane. This change is predicted to be tolerated by both SIFT and 
PolyPhen, though some transcripts are predicted to undergo nonsense mediated decay when this 
variant is present. Rs3736032 occurs with a MAF of 15%, so it is relatively common. Variants in 
SLC25A37 have been linked to iron imbalances
162,163
. Iron dysregulation occurs in Parkinson’s 
disease
164
 and has been related to other brain diseases
165
. Outside of neurodegenerative diseases,  
this SNP has been evaluated for gene environment interactions between iron intake and type 2 
diabetes
166
, but was not found to be significant.  
Since haplogroup J has been previously associated with similar phenotypes, it is not clear 
if the effects reported in the literature are due independently to haplogroup J, are caused by 
group J individuals with this SNP, or some combination of the two. It is likely that both J and the 
SNP together exaggerate the effect, but J alone causes enough of an effect to see in targeted 
association studies. In our PheWAS (Appendix M), haplogroup J appeared to modify the effect 
of a number of different SNPs on this phenotype, but all three SNPs that were near the top of our 
results were in different genes on different chromosomes and appear to have different functions. 
Further exploration will be necessary to untangle this relationship.  
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While the association of rs17850652 and Tobacco Use Disorder modified by haplogroup 
H, was unexpected, it is not completely unreasonable. rs17850652 is a global 10% MAF variant 
that causes a Lys291Arg change in RARS2. RARS2 is the Mitochondrial Arginyl-TRNA 
Synthetase 2. This change is thought to be benign. As RARS2 is involved in translation of 
mitochondrial encoded proteins, any number of defects could result from a small change in 
protein functionality, but most likely oxidative phosphorylation would be altered slightly.  
Mutations in RARS2 have been associated with Pontocerebellar hypoplasia, a rare 
neurodegenerative disorder
167
. We cannot provide a specific mechanism for how haplogroup 
might affect Tobacco Use Disorder, though there is a  small literature on smoking and 
mitochondria. We initially thought that this phenotype might be indicative of an underling 
predisposition to addiction, but no other signals for addiction are present in our PheWAS. 
Despite this, manual review of the records of patients with this PheWAS code indicate that they 
are smokers, consistent with reports about the reliability of smoking status in ICD-9 codes
168
.  
 We used three different models to test whether mitochondrial haplogroups modify the 
effects of SNPs involved in mitochondrial function. As there are no known positive associations 
for mitochondrial modification of SNP effects, we could not evaluate our models against a 
known standard, so we instead compared them to each other. The similarity of effect in the three 
models is highly dependent on the specific SNP, haplogroup, and phenotype tested. Much of the 
time, the three models gave similar effect sizes for the SNP or SNP-haplogroup co-occurence, 
but not always. One of the things that seemed to effect this was how each of the haplogroups 
contributed to the signal. When testing a SNP, we limit our analysis to biallelic SNPs. For 
haplogroups, individuals not of the haplogroup being tested can be from any of the 4 other 
common European haplogroups or can be grouped into the “other” category. So not-H 
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individuals are not all the same, but belong to one of the other haplogroups. We envisioned two 
scenarios; one in which one haplogroup showed an effect and the others all showed no effect or 
the same opposite effect, and one where two haplogroup show effects in opposite directions and 
the rest have no effect. More specific examples will have to be extracted and interrogated to 
understand the variety of effects we will and will not be able to see with each of these models. 
While we tested traditional interaction models, we were worried that the models accounting for 
the main effects of both the SNP, haplogroup, and the SNP and haplogroup co-occurring together 
might sometimes cancel out the effect in the scenario where different haplogroups have different 
effects. 
The main effects model accounts for the disease prevalence in individuals with the SNP- 
haplogroup combination, just the SNP, or just the haplogroup simultaneously. The mt mediated 
effect model compares disease prevalence in individuals with the SNP and haplogroup to those 
without the SNP-haplogroup combination. This is more similar to the mt haplogroup analysis 
methods comparing the haplogroup to the not-haplogroup population. Testing the co-occurrence 
of the SNP-haplogroup without the main effects of either might allow us to best evaluate 
scenarios where the SNP and haplogroup have no effect except together. We can still detect a 
signal when they each do have an effect, but then we are not properly accounting for it, and may 
inadvertently inflate the association of the combined occurrence. Our third model, stratifying by 
haplogroup and testing the SNP of interest in that group causes us to lose power, but provides the 
most intuitive and easily interpretable model.   
 An interesting side point from this analysis was the general lack of signal from 
haplogroups. Nothing we saw using any of the major European haplogroups as a predictors 
passed the Bonferroni correction for a single PheWAS. This was not completely unexpected as 
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mitochondrial haplogroups tend to have far more moderate significant effects than many SNPs, 
but we had assumed that as we were testing a wide variety of phenotypes, mitochondrial 
haplogroups would be significantly associated with at least one.   
A major issue we encountered in this study was sample size. While haplogroup H seemed 
large enough to allow us sufficient power to see at least some associations, for lower frequency 
haplogroups we had limited power. Perhaps the only reason we were able to detect any signal in 
haplogroup J was the strong effect. In retrospect, combining haplogroups J and T may have 
allowed us more power to see an association, and as they are in the same clade, would be 
biologically reasonable. A higher cut off for the number of cases necessary for PheWAS to be 
performed would also have been helpful. We used a minimum of 50 cases, but perhaps scaling 
this number based on the frequency of the SNP-haplogroup combination would have been better.  
Future directions include trying to replicate the results we have seen. We have begun 
looking within BioVU to validate the associations we have seen with more carefully phenotyped 
data. We would also like to replicate in an external dataset. A dataset used for GWAS, where a 
large number of individuals have been carefully phenotyped and have genetic data available 
would be ideal. We are currently evaluating the hits we think are biologically reasonable to find 
those that have Phecode associations that have existing GWAS proxies. As we were limited to 
Europeans by the nature of haplogroups, it would also be interesting to repeat this analysis in 
other population groups. 
 In vitro studies evaluating the impact of specific SNPs we think might be modified by 
mitochondrial haplogroup would be greatly helpful. Limited information is available for many of 
the genes and SNPs we have tested. In vitro studies to further explore the function of these genes 
and SNPs would help us evaluate our results for follow-up and also provide biological validation 
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for signals we think are real. Trying to decide if a SNP is reasonable is far more difficult when 
the gene has no annotated function. Additionally, for some of the genes on the MitoCarta2 list, it 
is not obvious how they might be relevant to mitochondrial function. The breadth of 
mitochondrial involvement in cell function provides us room to speculate in these cases, but our 
ability to draw biologically relevant connections to phenotypes is more complicated for these 
genes.  
In conclusion, PheWAS seems to be an interesting and adequate way to evaluate the 
potential of mitochondrial haplogroup to modify SNP effects. We saw what we think are 
biologically reasonable associations between the SNP, haplogroup, and phenotype. More 
stringent evaluation of the models will be necessary to determine which is best, though it may be 
that different models are ideal depending on the hypothesis. Further exploration of mechanisms 
to correct for multiple testing in this scenario would assist us in prioritizing the signals we saw 
and guide efforts for statistical or biological validation.  
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CONCLUSION 
 
My dissertation explores a variety of scenarios under which PheWAS is a reasonable 
technique to implement. The projects presented here begin with the most straight-forward 
scenario, directly genotyped single SNPs, and progress to imputed deletions before exploring 
ways to use PheWAS in multi-dimensional studies.  
One of the things that has struck me during my time using this technique is how different 
the follow-up to a PheWAS can be depending on the goal of the study, the existing knowledge of 
the variant, and the expectations of those involved in the work. The majority of my studies 
immediately follow-up a PheWAS by moving down one level of aggregation in the data and 
focusing on the ICD-9 level data. Sometimes a Phecode is made up of many ICD9 codes and this 
provides no clarity, but occasionally looking at the ICD9 code data allows one to shift focus to 
something more specific. Chapter 2 of the work presented here is a great example of the latter, 
where focusing on ICD9 level data directed the rest of the follow-up we performed. Laboratory 
test data and CPT code data are two other data sources I have used for follow-up. Of these, CPT 
code data is by far the easier. Laboratory test data can be some of the most useful data in 
reassuring oneself of a PheWAS association, but can also be extremely complicated to quality 
control. I have encountered tests where the interpretation of results is highly dependent on the 
age of the individual at the time of the test. Tests often have unexpected values, such as a few 
instances when someone enters <30, while the majority of the entries are integers, or text entries 
indicated contaminated specimens will be mixed in with numeric measures. These problems 
have sometimes forced me to adapt my analysis plan to unexpected patterns in the data. Despite 
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these other options, manual review is the best mechanism to be sure that the PheWAS 
association you see truly represents a disorder in the data.  
 I feel that I did not really begin to appreciate all the nuance of the PheWAS method until 
I began to do higher dimensional analyses with the data and to think about how to compare 
different PheWAS outcomes to each other. I have found it difficult to identify how much of the 
correlation between codes in outcome is solely correlation in the ICD-9 codes used for 
aggregation and how much is actual or potential biology of the predictor tested. Studies using 
only SNPs of similar allele frequencies might be helpful to determine how much of the 
variability in PheWAS result is only due to allele frequency and how much is due to other 
factors.  
One interesting connection between almost all the analyses performed was that age or sex 
or both were often stronger predictors than any of the PheWAS codes themselves. While we tried 
to limit the impact of this by stratifying data appropriately, we were not always successful, 
especially when age played an important role. An interesting illustration of how insignificant 
genetic predictors appear to be overall can be seen by performing a PheWAS using sex as the 
primary predictor (adjusting for median age over record). The best p-value signal we saw from a 
genetic predictor in any of our analyses was ~1e-14 from a SNP in ARMS2 with age-related 
macular degeneration. Sex as a predictor, by contrast, results in many p-values less than 10e-30 
(Figure 6-A). While some of this is surely due to power, it still clearly realigns our expectations 
about what we should see from genetic predictors.  
 103 
 
Figure 6-A. PheWAS manhattan plot using sex as the primary predictor. European descent 
individuals with genotyping on the Exome chip were used. Adjusted for median age over record. 
 
 As we chose each of the types of genetic variation and many specific genetic variants for 
analysis, one interesting dilemma was presented to us that we may not have noticed if we had 
just analyzed everything. How does one proceed when a variant that is known to have disease 
associations does not result in any signal in PheWAS? In our case, as we were primarily 
analyzing variants one at a time, we were able to explore the silent phenotypes in our PheWAS, 
those that we expected but did not see. We often went back to refine the population to optimize 
our chances of seeing the association. In cases where we were analyzing many deletions or 
SNPs, we never did this. There may be interesting reasons that we see some but not all known 
associations represented in our PheWAS outcomes and without detailed exploration of both the 
genotypic and phenotypic specifics in the dataset we would miss them. This does leave us with 
the question of whether we should value any of the PheWAS if we cannot see what we might 
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expect to use as positive controls. The potential development of agnostic methods for prioritizing 
results from multiplexed PheWAS studies provides an interesting thought experiment, though I 
remain unconvinced that any simple method will sufficiently do so. In our analyses, using p-
values provided a preliminary, if occasionally insufficient, filter. Further filtering of the patterns 
of betas and the numbers of cases with the genetic predictor will most certainly be necessary to 
blindly evaluate many SNPs.  
 In conclusion, while I have found PheWAS to be a useful method for interrogating 
genotype-phenotype relationships, I think the merit of the approach lies in how it may direct you 
for future studies of the SNP, protein, or gene. While PheWAS can also be a useful tool for 
steering the learning about underlying biology of a genetic relationship, using it without any 
knowledge of the predictor makes it difficult to know how to interpret the results appropriately.  
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APPENDIX 
Appendix A. PheWAS result for top 25 hits in all individuals from ADRB2 Thr164Ile Analysis. 
PheWAS 
Code 
PheWAS Description SNP Beta OR SE p 
Total 
N 
Case 
N 
Control 
N 
Passes 
Bonferroni 
Passes 
FDR 
458.2 Iatrogenic hypotension Thr164Ile 1.606 4.983 0.379 2.25E-05 19180 56 19124 TRUE TRUE 
573.9 Abnormal serum enzyme levels Thr164Ile 0.914 2.495 0.229 6.50E-05 18862 336 18526 FALSE TRUE 
278.11 Morbid obesity Thr164Ile 0.597 1.817 0.162 2.23E-04 20356 905 19451 FALSE FALSE 
961 Poisoning by other anti-infectives Thr164Ile 1.432 4.186 0.402 3.72E-04 19235 56 19179 FALSE FALSE 
244.2 Acquired hypothyroidism Thr164Ile 1.094 2.987 0.317 5.45E-04 18240 136 18104 FALSE FALSE 
278.3 Localized adiposity Thr164Ile 1.336 3.804 0.402 8.85E-04 19512 61 19451 FALSE FALSE 
303 Psychogenic and somatoform disorders Thr164Ile 1.160 3.188 0.349 9.00E-04 15642 99 15543 FALSE FALSE 
276.42 Alkalosis Thr164Ile 0.992 2.697 0.315 1.64E-03 14885 154 14731 FALSE FALSE 
303.4 Somatoform disorder Thr164Ile 1.239 3.453 0.400 1.96E-03 15611 68 15543 FALSE FALSE 
41.9 Drug-resistant infection Thr164Ile 0.704 2.023 0.230 2.21E-03 20090 383 19707 FALSE FALSE 
530.14 Reflux esophagitis Thr164Ile 1.117 3.055 0.382 3.46E-03 14098 93 14005 FALSE FALSE 
550 Abdominal hernia Thr164Ile 0.386 1.471 0.132 3.47E-03 22302 1899 20403 FALSE FALSE 
260 Protein-calorie malnutrition Thr164Ile 0.400 1.491 0.137 3.57E-03 19088 1652 17436 FALSE FALSE 
297.1 Suicidal ideation Thr164Ile 1.261 3.529 0.436 3.80E-03 15598 55 15543 FALSE FALSE 
594.3 Calculus of ureter Thr164Ile 0.747 2.111 0.259 3.87E-03 22031 282 21749 FALSE FALSE 
369.5 Conjunctivitis, infectious Thr164Ile 0.852 2.344 0.317 7.15E-03 20450 166 20284 FALSE FALSE 
550.2 Diaphragmatic hernia Thr164Ile 0.514 1.672 0.193 7.60E-03 21141 738 20403 FALSE FALSE 
789 Nausea and vomiting Thr164Ile 0.259 1.296 0.101 1.04E-02 21444 4090 17354 FALSE FALSE 
337 
Disorders of the autonomic nervous 
system 
Thr164Ile 0.852 2.345 0.334 1.06E-02 18266 154 18112 FALSE FALSE 
369 Infection of the eye Thr164Ile 0.682 1.977 0.269 1.12E-02 20560 276 20284 FALSE FALSE 
512.2 Painful respiration Thr164Ile 0.634 1.886 0.252 1.18E-02 17302 342 16960 FALSE FALSE 
594 Urinary calculus Thr164Ile 0.433 1.543 0.173 1.22E-02 22657 908 21749 FALSE FALSE 
506 Empyema and pneumothorax Thr164Ile 0.441 1.555 0.178 1.30E-02 16199 866 15333 FALSE FALSE 
377.1 Optic atrophy Thr164Ile 1.119 3.060 0.453 1.35E-02 20619 67 20552 FALSE FALSE 
 120 
Appendix B. PheWAS result for top 25 hits in females only from ADRB2 Thr164Ile Analysis. 
PheWAS 
Code PheWAS Description SNP Beta OR SE p 
Total 
N Case N 
Control 
N 
Passes 
Bonferroni 
Passes 
FDR 
458.2 Iatrogenic hypotension The164Ile 2.015 7.503 0.426 2.26E-06 10636 32 10604 TRUE TRUE 
244.2 Acquired hypothyroidism The164Ile 1.535 4.640 0.347 9.57E-06 8959 81 8878 TRUE TRUE 
573.9 Abnormal serum enzyme levels The164Ile 1.143 3.135 0.286 6.57E-05 10325 167 10158 FALSE TRUE 
41.9 Drug-resistant infection The164Ile 1.068 2.909 0.273 9.10E-05 10958 192 10766 FALSE TRUE 
703.1 Ingrowing nail The164Ile 1.354 3.874 0.363 1.89E-04 11887 80 11807 FALSE TRUE 
480 Pneumonia The164Ile 0.500 1.649 0.150 8.67E-04 11093 1427 9666 FALSE FALSE 
961 Poisoning by other anti-infectives The164Ile 1.491 4.442 0.450 9.19E-04 10438 44 10394 FALSE FALSE 
303 
Psychogenic and somatoform 
disorders The164Ile 1.215 3.372 0.384 1.55E-03 7824 80 7744 FALSE FALSE 
278.3 Localized adiposity The164Ile 1.361 3.900 0.445 2.21E-03 10351 47 10304 FALSE FALSE 
550.2 Diaphragmatic hernia The164Ile 0.696 2.005 0.231 2.58E-03 11682 428 11254 FALSE FALSE 
506 Empyema and pneumothorax The164Ile 0.697 2.007 0.234 2.93E-03 9160 393 8767 FALSE FALSE 
481 Influenza The164Ile 1.144 3.139 0.386 3.06E-03 9759 93 9666 FALSE FALSE 
41 Bacterial infection NOS The164Ile 0.457 1.579 0.156 3.34E-03 12016 1250 10766 FALSE FALSE 
292.4 Altered mental status The164Ile 0.577 1.780 0.197 3.38E-03 10181 657 9524 FALSE FALSE 
705 Disorders of sweat glands The164Ile 1.436 4.202 0.500 4.12E-03 11368 37 11331 FALSE FALSE 
512.2 Painful respiration The164Ile 0.838 2.313 0.292 4.15E-03 9594 200 9394 FALSE FALSE 
303.4 Somatoform disorder The164Ile 1.282 3.603 0.450 4.36E-03 7797 53 7744 FALSE FALSE 
783 Fever of unknown origin The164Ile 0.406 1.501 0.143 4.36E-03 11650 1706 9944 FALSE FALSE 
591 Urinary tract infection The164Ile 0.355 1.426 0.127 5.04E-03 10876 2782 8094 FALSE FALSE 
189.4 
Malignant neoplasm of kidney and 
other urinary organs The164Ile 1.414 4.113 0.511 5.65E-03 12481 37 12444 FALSE FALSE 
939 Atopic or contact dermatitis The164Ile 0.531 1.701 0.196 6.63E-03 10899 689 10210 FALSE FALSE 
276.1 Electrolyte imbalance The164Ile 0.362 1.437 0.134 6.68E-03 10569 2475 8094 FALSE FALSE 
327.3 Sleep apnea The164Ile 0.566 1.761 0.210 6.98E-03 10809 555 10254 FALSE FALSE 
384.4 Perforation of tympanic membrane The164Ile 1.372 3.943 0.509 7.05E-03 11269 39 11230 FALSE FALSE 
530.14 Reflux esophagitis The164Ile 1.245 3.474 0.463 7.18E-03 7676 60 7616 FALSE FALSE 
594 Urinary calculus The164Ile 0.650 1.915 0.242 7.18E-03 12306 363 11943 FALSE FALSE 
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Appendix C. PheWAS results for phenotypes we had anticipated might be associated with ADRB2 Thr164Ile prior to analysis. 
 
PheWAS Description SNP Beta OR SE p Total  N Case N Control N 
All 
         
 
Hypertension Thr164Ile 0.114982 1.121854 0.094509 0.223747 21474 11444 10030 
 
Essential hypertension Thr164Ile 0.129056 1.137754 0.094806 0.173431 21268 11238 10030 
 
Asthma Thr164Ile 0.197687 1.218581 0.166332 0.234633 20053 1284 18769 
 
Chronic obstructive asthma Thr164Ile 0.450507 1.569108 0.382303 0.238635 18948 179 18769 
 
Chronic obstructive asthma with 
exacerbation Thr164Ile NA NA NA NA 18804 35 18769 
 
Asthma with exacerbation Thr164Ile 0.438416 1.55025 0.37969 0.248225 18950 181 18769 
Females 
         
 
Hypertension The164Ile 0.128784 1.137445 0.130667 0.324333 11702 5795 5907 
 
Essential hypertension The164Ile 0.147349 1.158758 0.130903 0.260319 11612 5705 5907 
 
Asthma The164Ile 0.256596 1.292523 0.196963 0.192655 11005 881 10124 
 
Chronic obstructive asthma The164Ile -0.00458 0.995428 0.585769 0.993758 10240 116 10124 
 
Chronic obstructive asthma with 
exacerbation The164Ile 0.371146 1.449394 1.008659 0.712903 10151 27 10124 
 
Asthma with exacerbation The164Ile 0.524153 1.689028 0.415364 0.20698 10264 140 10124 
Males 
         
 
Hypertension Thr164Ile 0.094461 1.099067 0.138747 0.495986 9745 5634 4111 
 
Essential hypertension Thr164Ile 0.103523 1.109071 0.139317 0.457436 9630 5519 4111 
 
Asthma Thr164Ile 0.02469 1.024997 0.320546 0.938604 9030 402 8628 
 
Chronic obstructive asthma Thr164Ile 0.964345 2.623069 0.500894 0.054199 8691 63 8628 
 
Chronic obstructive asthma with 
exacerbation Thr164Ile NA NA NA NA 8636 8 8628 
 
Asthma with exacerbation Thr164Ile 0.018239 1.018406 0.995608 0.985384 8669 41 8628 
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Appendix D. ICD-9 codes mapping to PheWAS codes discussed in Chapter 1. PheWAS Code 
Name and number are bolded followed by all ICD-9 codes in that mapping. 
Iatrogenic 
Hypotension (458.2) 
Poisoning by Other 
Anti-infectives (961) 
Pneumonia (480) 
Continued 
Pneumonia (480) 
Continued 
458.2 961 112.4 482.89 
458.21 961.1 114.0 482.9 
458.29 961.2 114.4 483 
 961.3 114.5 483.0 
Serum Enzyme 
Abnormalities (573.9) 
961.4 130.4 483.1 
961.5 136.3 483.8 
790.5 961.6 480 484 
 
961.7 480.0 484.1 
Drug-resistant 
Infection (041.9) 
961.9 480.1 484.3 
E857 480.2 484.5 
V09 E931 480.3 484.6 
V09.0 E931.1 480.8 484.7 
V09.1 E931.2 480.9 484.8 
V09.2 E931.3 481 485 
V09.3 E931.4 481.0 485.0 
V09.4 E931.5 482 486 
V09.5 E931.6 482.0 513 
V09.50 E931.7 482.1 513.0 
V09.51 E931.9 482.2 513.1 
V09.6 V14.3 482.3 517.1 
V09.7  482.30 V12.61 
V09.70 Pneumonia (480) 482.31  
V09.71 003.22 482.32  
V09.8 020.3 482.39  
V09.80 020.4 482.4  
V09.81 020.5 482.40  
V09.9 021.2 482.41 
 
V09.90 022.1 482.42 
 
V09.91 031.0 482.49 
 
 039.1 482.8 
 
Acquired Hypotension 
(244.2) 
052.1 482.81 
 
055.1 482.82 
 
244.8 073.0 482.83 
 
 
083.0 482.84 
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Appendix E. Top 25 PheWAS hits for all individuals from the A3G His186Arg analysis. 
PheWAS 
Code PheWAS Description SNP Beta OR SE p Total N Case N Control N 
279.11 Deficiency of humoral immunity His186Arg 1.075 2.930 0.239 7.01E-06 25271 108 25163 
292.6 Hallucinations His186Arg 1.119 3.061 0.316 3.96E-04 20674 64 20610 
597 Other disorders of urethra and urinary tract His186Arg 0.502 1.652 0.166 2.42E-03 24887 400 24487 
452 Venous embolism & thrombosis His186Arg -0.413 0.661 0.138 2.65E-03 22086 1396 20690 
242 Thyrotoxicosis His186Arg 0.471 1.602 0.160 3.20E-03 22032 441 21591 
174.3 Neoplasm of uncertain behavior of breast His186Arg 0.843 2.324 0.312 6.81E-03 23780 81 23699 
573.5 Jaundice His186Arg 0.461 1.585 0.172 7.52E-03 22159 370 21789 
242.1 Graves' disease His186Arg 0.557 1.745 0.210 8.02E-03 21821 230 21591 
333 
Extrapyramidal disease and abnormal movement 
disorders His186Arg -0.618 0.539 0.239 9.79E-03 21494 550 20944 
771 Musculoskeletal symptoms referable to limbs His186Arg 0.531 1.701 0.206 1.01E-02 24066 252 23814 
117 Mycoses His186Arg -0.860 0.423 0.355 1.55E-02 23965 299 23666 
306 Random mental disorder. Ignored for now His186Arg 0.698 2.010 0.295 1.80E-02 18704 97 18607 
596.5 Functional disorders of bladder His186Arg 0.353 1.423 0.152 2.02E-02 25016 529 24487 
334 Degenerative disease of the spinal cord His186Arg -0.701 0.496 0.304 2.12E-02 21302 358 20944 
270 
Protein plasma/amino-acid transport and 
metabolism disorder His186Arg -0.519 0.595 0.226 2.20E-02 26060 544 25516 
270.3 Plasma protein metabolism disorder His186Arg -0.594 0.552 0.261 2.29E-02 25961 445 25516 
426.91 Cardiac pacemaker in situ His186Arg 0.287 1.333 0.127 2.34E-02 17613 948 16665 
281.11 Pernicious anemia His186Arg 0.544 1.722 0.248 2.84E-02 17501 170 17331 
371.21 Allergic conjunctivitis His186Arg -0.689 0.502 0.320 3.13E-02 24018 322 23696 
333.4 Torsion dystonia His186Arg -2.133 0.118 1.001 3.31E-02 21082 138 20944 
695.41 Lupus erythematosus His186Arg 0.676 1.966 0.324 3.72E-02 23093 85 23008 
550.6 Incisional hernia His186Arg 0.370 1.448 0.179 3.87E-02 24315 383 23932 
275.5 Calcium/phosphorus disorders His186Arg -0.341 0.711 0.165 3.92E-02 25182 851 24331 
362.3 NA His186Arg 0.512 1.669 0.248 3.93E-02 27309 174 27135 
470 Deviated nasal septum His186Arg -0.390 0.677 0.189 3.96E-02 20008 700 19308 
279.11 Deficiency of humoral immunity His186Arg 1.075 2.930 0.239 7.01E-06 25271 108 25163 
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Appendix F.Top 25 PheWAS hits for individuals under the age of 20 at their last ICD9 code record from the A3G His186Arg analysis. 
PheWAS 
Code PheWAS Description SNP Beta OR SE p Total N Case N Control N 
279.11 Deficiency of humoral immunity His186Arg 1.714 5.549 0.383 7.73E-06 3557 27 3530 
870.3 Other open wound of head and face His186Arg 1.342 3.828 0.434 1.98E-03 3517 24 3493 
714.1 Rheumatoid arthritis His186Arg 1.021 2.775 0.366 5.35E-03 3579 43 3536 
244 Hypothyroidism His186Arg 0.687 1.987 0.263 9.01E-03 3684 123 3561 
788 Syncope and collapse His186Arg 0.809 2.245 0.313 9.73E-03 3696 76 3620 
687.1 Rash and other nonspecific skin eruption His186Arg 0.547 1.728 0.220 1.31E-02 3519 210 3309 
389.2 Conductive hearing loss His186Arg 0.580 1.786 0.234 1.31E-02 3560 176 3384 
327.32 Obstructive sleep apnea His186Arg 0.746 2.108 0.307 1.53E-02 3573 86 3487 
327 Sleep disorders His186Arg 0.568 1.765 0.245 2.05E-02 3649 162 3487 
507 Pleurisy; pleural effusion His186Arg -0.775 0.461 0.345 2.48E-02 3266 263 3003 
597 Other disorders of urethra and urinary tract His186Arg 1.055 2.871 0.479 2.76E-02 3465 27 3438 
588.2 Secondary hyperparathyroidism (of renal origin) His186Arg 1.047 2.848 0.477 2.82E-02 3274 26 3248 
599.4 Urinary incontinence His186Arg 0.715 2.045 0.329 2.96E-02 3374 77 3297 
244.4 NA His186Arg 0.623 1.864 0.288 3.08E-02 3790 107 3683 
599 Symptoms/disorders of the urinary system His186Arg 0.491 1.634 0.232 3.41E-02 3496 199 3297 
261.4 Vitamin D deficiency His186Arg 0.807 2.242 0.383 3.53E-02 2665 47 2618 
851 Complications of transplants and reattached limbs His186Arg 0.939 2.558 0.464 4.30E-02 3384 29 3355 
327.3 Sleep apnea His186Arg 0.551 1.735 0.274 4.39E-02 3617 130 3487 
327.4 Insomnia His186Arg 1.029 2.797 0.513 4.48E-02 3509 22 3487 
242 Thyrotoxicosis His186Arg 1.013 2.755 0.506 4.53E-02 3583 22 3561 
870 Open wounds of head; neck; and trunk His186Arg 0.655 1.924 0.333 4.93E-02 3568 75 3493 
809 Fracture of unspecified bones His186Arg -1.957 0.141 1.003 5.11E-02 3414 101 3313 
416 Cardiomegaly His186Arg -0.618 0.539 0.318 5.24E-02 3650 257 3393 
506 Empyema and pneumothorax His186Arg -1.947 0.143 1.006 5.29E-02 3096 93 3003 
428.4 NA His186Arg -1.940 0.144 1.013 5.55E-02 3828 75 3753 
579 Other symptoms involving abdomen and pelvis His186Arg -1.919 0.147 1.005 5.63E-02 3316 93 3223 
395 Heart valve disorders His186Arg -0.972 0.378 0.510 5.66E-02 3374 140 3234 
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Appendix G. List of all ICD9 codes that map to the Deficiency of Humoral Immunity PheWAS 
code discussed in chapter 2. 
Deficiency of Humoral Immunity (279.11) 
279.0 
279.00 
279.01 
279.02 
279.03 
279.04 
279.05 
279.06 
279.09 
 
 
Appendix H. Screenshot of Vanderbilt Pathology Laboratory Services Test Directory showing 
Reference ranges of IGG Quantitative Blood Test. 
 126 
Appendix I. Top 24 hits from PheWAS of the A3B deletion in all individuals. 
PheWAS 
Code PheWAS Description SNP Beta OR SE p 
Total 
N 
Case 
N 
Control 
N 
Passes 
Bonferroni 
Passes 
FDR 
Passes 
SimpleM 
428.2 Heart failure NOS A3B 0.720 2.054 0.167 1.55E-05 2732 262 2470 TRUE TRUE TRUE 
428.1 Systolic/diastolic heart failure A3B 0.518 1.678 0.123 2.42E-05 3250 780 2470 TRUE TRUE TRUE 
395.2 Nonrheumatic aortic valve disorders A3B 0.700 2.013 0.167 2.77E-05 3220 247 2973 TRUE TRUE TRUE 
395 Heart valve disorders A3B 0.490 1.633 0.124 7.81E-05 3564 591 2973 FALSE TRUE TRUE 
428 Heart failure A3B 0.462 1.587 0.119 1.01E-04 3345 875 2470 FALSE TRUE TRUE 
427.9 Palpitations A3B 0.577 1.781 0.164 4.22E-04 2059 350 1709 FALSE FALSE TRUE 
440 Atherosclerosis A3B 0.556 1.744 0.161 5.61E-04 3094 302 2792 FALSE FALSE FALSE 
425 Cardiomyopathy A3B 0.472 1.604 0.142 8.85E-04 3638 379 3259 FALSE FALSE FALSE 
426 Cardiac conduction disorders A3B 0.462 1.587 0.141 1.02E-03 2364 655 1709 FALSE FALSE FALSE 
429.9 
Cardiac complications, not 
elsewhere classified 
A3B 
1.177 3.244 0.371 1.51E-03 2502 32 2470 FALSE FALSE FALSE 
415.21 NA A3B 0.857 2.357 0.271 1.59E-03 3956 62 3894 FALSE FALSE FALSE 
427 Cardiac dysrhythmias A3B 0.324 1.383 0.107 2.49E-03 3371 1662 1709 FALSE FALSE FALSE 
442 Other aneurysm A3B 0.618 1.855 0.205 2.57E-03 2952 160 2792 FALSE FALSE FALSE 
426.92 Cardiac defibrillator in situ A3B 0.599 1.820 0.201 2.86E-03 1914 205 1709 FALSE FALSE FALSE 
442.1 Aortic aneurysm A3B 0.672 1.958 0.227 3.10E-03 2914 122 2792 FALSE FALSE FALSE 
579.2 NA A3B 0.817 2.263 0.281 3.62E-03 3920 59 3861 FALSE FALSE FALSE 
761 Neck pain A3B -0.695 0.499 0.239 3.63E-03 3747 301 3446 FALSE FALSE FALSE 
426.9 Cardiac pacemaker/device in situ A3B 0.487 1.628 0.169 4.05E-03 2092 383 1709 FALSE FALSE FALSE 
427.21 Atrial fibrillation A3B 0.412 1.509 0.145 4.48E-03 2470 761 1709 FALSE FALSE FALSE 
395.1 Nonrheumatic mitral valve disorders A3B 0.433 1.541 0.152 4.50E-03 3349 376 2973 FALSE FALSE FALSE 
427.22 Atrial flutter A3B 0.616 1.852 0.220 5.09E-03 1897 188 1709 FALSE FALSE FALSE 
425.1 Primary/intrinsic cardiomyopathies A3B 0.424 1.528 0.151 5.09E-03 3595 336 3259 FALSE FALSE FALSE 
428.3 NA A3B 0.447 1.564 0.160 5.17E-03 3904 290 3614 FALSE FALSE FALSE 
394 
Chronic rheumatic disease of the 
heart valves 
A3B 
0.586 1.797 0.211 5.46E-03 3126 153 2973 FALSE FALSE FALSE 
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Appendix J. ICD-9 Codes that map to each of the PheWAS codes discussed in chapter 3. 
Heart Failure NOS 
(428.2) 
Heart Failure 
(428) 
428.1 398.91 
428.9 428 
 428.0 
Nonrheumatic Aortic 
Valve Disorders (395.2) 
428.00 
428.1 
424.1 428.2 
 428.20 
Systolic/Diastolic Heart 
Failure (428.1) 
428.21 
428.22 
398.91 428.23 
428.00 428.3 
428.0 428.30 
 428.31 
Heart Valve Disorders 
(395) 
428.32 
428.33 
424 428.4 
424.0 428.40 
424.1 428.41 
424.2 428.42 
424.3 428.43 
424.91 428.9 
V42.2  
V43.3  
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Appendix K. Top 10 PheWAS hits from deletions annotated as overlapping genes. No deletions appear twice in the top 10. 
PheWAS 
Code PheWAS Description ESV Beta OR SE p Total N Case N Control N 
704.8 Other specified diseases of hair and hair follicles esv2673257 1.271 3.563 0.267 2.02E-06 4428 51 4377 
255.2 Adrenal hypofunction esv2670116 0.930 2.535 0.200 3.13E-06 3994 88 3906 
367.2 Astigmatism esv2664484 1.894 6.649 0.420 6.38E-06 4429 21 4408 
41.12 Methicillin resistant Staphylococcus aureus esv2663159 0.804 2.235 0.179 7.27E-06 3223 121 3102 
530.12 Ulcer of esophagus esv2667558 1.662 5.271 0.374 8.65E-06 2368 27 2341 
355 Complex regional/central pain syndrome esv2666201 1.385 3.995 0.313 9.53E-06 3924 29 3895 
574.3 Cholecystitis without cholelithiasis esv2671657 0.823 2.277 0.187 1.12E-05 4218 81 4137 
348.1 NA esv2677892 0.312 1.366 0.072 1.48E-05 3615 463 3152 
117 Mycoses esv2664490 0.892 2.440 0.207 1.68E-05 3940 124 3816 
272.1 Hyperlipidemia esv2673043 0.209 1.232 0.049 1.90E-05 4203 2219 1984 
 
Appendix L. Top 10 PheWAS hits from deletions not annotated as overlapping genes. Color-coding represents unique signals. 
PheWAS 
Code PheWAS Description ESV Beta OR SE p Total N Case N Control N 
250.1 Type 1 diabetes esv2673441 -0.519 0.595 0.078 2.70E-11 3040 472 2568 
250.12 Type 1 diabetes with renal manifestations esv2673441 -1.014 0.363 0.160 2.46E-10 2696 128 2568 
250.11 Type 1 diabetes with ketoacidosis esv2673441 -0.731 0.481 0.123 2.69E-09 2759 191 2568 
290.11 Alzheimer's disease esv2659215 2.213 9.142 0.404 4.42E-08 3153 25 3128 
272 Disorders of lipoid metabolism esv2672272 -0.362 0.696 0.067 5.82E-08 2595 1361 1234 
272.1 Hyperlipidemia esv2672272 -0.356 0.701 0.067 1.03E-07 2587 1353 1234 
250.13 Type 1 diabetes with ophthalmic manifestations esv2673441 -1.043 0.353 0.205 3.62E-07 2646 78 2568 
250.7 Diabetic retinopathy esv2673441 -0.589 0.555 0.120 9.33E-07 2754 186 2568 
272.11 Hypercholesterolemia esv2672272 -0.420 0.657 0.086 1.16E-06 1842 608 1234 
415.2 Chronic pulmonary heart disease esv2657961 0.816 2.262 0.173 2.29E-06 3483 72 3411 
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Appendix M. Top 15 hits for the SNP-Haplogroup term in haplogroup J. 
PheWAS 
Code PheWAS Description Exome SNP Haplogroup Beta SE P 
Case 
N 
Control 
N 
Total 
N 
331 Other cerebral degenerations exm689825_A J 1.601 0.239 2.03E-11 287 15349 15636 
705.8 Generalized hyperhidrosis exm381852_T J 1.793 0.331 6.09E-08 69 17721 17790 
612 
Breast conditions, congenital or relating to 
hormones exm1036183_A J 1.958 0.362 6.31E-08 102 16954 17056 
724 Other disorders of back exm631536_C J 1.808 0.337 8.07E-08 80 15609 15689 
337 Disorders of the autonomic nervous system exm1649321_T J 1.165 0.223 1.86E-07 132 15347 15479 
303.4 Somatoform disorder exm1623703_C J 1.746 0.338 2.37E-07 56 13106 13162 
337 Disorders of the autonomic nervous system exm1013046_T J 1.622 0.315 2.51E-07 131 15298 15429 
612.2 Hypertrophy of breast (Gynecomastia) exm1036183_A J 1.955 0.385 3.92E-07 85 16954 17039 
331 Other cerebral degenerations exm855988_T J 0.615 0.123 5.43E-07 287 15339 15626 
573.5 Jaundice exm869579_T J 0.910 0.182 6.06E-07 206 15875 16081 
250.14 Type 1 diabetic neuropathy exm117637_G J 1.203 0.245 8.83E-07 194 13545 13739 
281.12 Vitamin B12 deficiency anemia exm1013046_T J 1.579 0.326 1.28E-06 160 12181 12341 
331 Other cerebral degenerations exm1496803_G J 0.576 0.119 1.30E-06 287 15349 15636 
427.22 Atrial flutter exm1013725_G J 0.723 0.152 1.97E-06 534 11561 12095 
703 Diseases of nail exm137983_A J 1.496 0.315 2.01E-06 98 18641 18739 
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Appendix N. Top 15 PheWAS hits for the SNP-Haplogroup term in haplogroup H. 
PheWAS 
Code PheWAS Description Exome SNP Haplogroup Beta SE P 
Case 
N 
Control 
N 
Total 
N 
595 Hydronephrosis exm473294_G H 0.399 0.071 2.11E-08 379 18311 18690 
153.3 Cancer of the lower GI tract exm1523019_T H 0.563 0.107 1.36E-07 384 15722 16106 
153.3 Cancer of the lower GI tract exm1522975_A H 0.563 0.107 1.37E-07 384 15723 16107 
595 Hydronephrosis exm200699_A H 0.388 0.076 4.06E-07 379 18291 18670 
110.13 Dermatophytosis of the body exm620674_C H 1.203 0.240 5.45E-07 63 17059 17122 
318 Tobacco use disorder exm564892_C H 0.430 0.088 1.12E-06 1456 16682 18138 
172.1 Melanoma exm720018_T H 0.449 0.092 1.21E-06 1039 15302 16341 
595 Hydronephrosis exm60331_G H 0.445 0.092 1.27E-06 379 18315 18694 
357 Inflammatory and toxic neuropathy exm1043475_T H 0.960 0.200 1.55E-06 100 17700 17800 
357 Inflammatory and toxic neuropathy exm1043475_T H 0.960 0.200 1.55E-06 100 17700 17800 
153 Colorectal cancer exm1523019_T H 0.377 0.079 1.77E-06 879 15722 16601 
599.3 Dysuria exm869611_A H 0.402 0.084 1.79E-06 843 14099 14942 
153 Colorectal cancer exm1522975_A H 0.377 0.079 1.81E-06 879 15723 16602 
276.42 Alkalosis exm620881_T H 1.032 0.218 2.26E-06 121 12470 12591 
642 Hypertension complicating pregnancy exm1065549_C H 1.253 0.272 4.23E-06 93 19562 19655 
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Appendix O. Mapping of ICD9 codes to PheWAS codes discussed in chapter 5. PheWAS code 
description and number are listed above the mapped ICD9 codes.  
OtherCerebral Degenerations (331) 
330 
330.8 
331.81 
331.89 
331.9 
331 
330.3 
330.1 
330.9 
331.6 
330.2 
330 
331.3 
331.8 
331.4 
331.7 
331.5 
 Tobacco Use Disorder (318) 
649 
305.11 
649.04 
305.12 
649 
305.1 
305.13 
649.02 
649.03 
305.1 
649.01 
 
 
 
 
 
